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Abstract
The brain is unique among organs in many respects, including its mechanisms of lipid synthesis and energy production. The nervous system-
specific metabolite N-acetylaspartate (NAA), which is synthesized from aspartate and acetyl-coenzyme A in neurons, appears to be a key link in
these distinct biochemical features of CNS metabolism. During early postnatal central nervous system (CNS) development, the expression of
lipogenic enzymes in oligodendrocytes, including the NAA-degrading enzyme aspartoacylase (ASPA), is increased along with increased NAA
production in neurons. NAA is transported from neurons to the cytoplasm of oligodendrocytes, where ASPA cleaves the acetate moiety for use in
fatty acid and steroid synthesis. The fatty acids and steroids produced then go on to be used as building blocks for myelin lipid synthesis. Mutations
in the gene for ASPA result in the fatal leukodystrophy Canavan disease, for which there is currently no effective treatment. Once postnatal
myelination is completed, NAA may continue to be involved in myelin lipid turnover in adults, but it also appears to adopt other roles, including a
bioenergetic role in neuronal mitochondria. NAA and ATP metabolism appear to be linked indirectly, whereby acetylation of aspartate may
facilitate its removal from neuronal mitochondria, thus favoring conversion of glutamate to alpha ketoglutarate which can enter the tricarboxylic
acid cycle for energy production. In its role as a mechanism for enhancing mitochondrial energy production from glutamate, NAA is in a key
position to act as a magnetic resonance spectroscopy marker for neuronal health, viability and number. Evidence suggests that NAA is a direct
precursor for the enzymatic synthesis of the neuron specific dipeptideN-acetylaspartylglutamate, the most concentrated neuropeptide in the human
brain. Other proposed roles for NAA include neuronal osmoregulation and axon-glial signaling. We propose that NAA may also be involved in
brain nitrogen balance. Further research will be required to more fully understand the biochemical functions served by NAA in CNS development
and activity, and additional functions are likely to be discovered.
Published by Elsevier Ltd.
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1. Introduction
N-Acetylaspartate (NAA, Fig. 1) is an enigmatic molecule
present at exceptionally high concentrations in the brain (Tallan
et al., 1956; Tallan, 1957). The levels found in various areas of
the brain can reach 10 mM or greater (Bluml, 1999; Miyake
et al., 1981; Pan and Takahashi, 2005), making it one of the
most concentrated molecules in the CNS. After five decades of
research by neuroscientists and clinicians into the roles played
by NAA, its metabolic and neurochemical functions remain
controversial, and its connections to several disease states are
uncertain. For three decades after its discovery, NAA research
was limited to a few laboratories scattered around the world,
and progress was slow. There were two seminal findings that
brought NAA to the attention of the general neuroscience and
neurology communities, dramatically accelerating the pace of
research into the neurochemistry and neurobiology of this
unique molecule. First was the prominence of the NAA proton
signal in magnetic resonance spectroscopy (MRS), making
NAA one of the most reliable markers for brain MRS studies
(Barany et al., 1987; Fan et al., 1986; Luyten and den
Fig. 1. Chemical structure of NAA (mw 173 Da in the ionic form). The
acetate moiety (CH3CO) is on the left, and is attached through the amine
nitrogen of aspartate. The three roughly equivalent methyl hydrogen atoms on
the acetate group resonatewith a frequency shift of 2.02 ppm relative to anMRS
standard.
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Hollander, 1986). The second was the connection to the rare but
fatal hereditary genetic disorder known as Canavan disease
(Bartalini et al., 1992; Divry and Mathieu, 1989; Hagenfeldt
et al., 1987; Matalon et al., 1988).
In the case of Canavan disease, it was found that a mutation
in the gene for the enzyme aspartoacylase (ASPA; EC 3.5.1.15)
resulted in an inability to catabolize NAA, leading to a
progressive, fatal leukodystrophy in affected infants. In the case
of the prominent NAA signal in MRS, it was found that the
levels of NAA in various parts of the brain correlate with
neuronal health or integrity. Decreased levels of NAA as
detected by MRS have been interpreted to indicate neuronal/
axonal loss, or compromised neuronal metabolism. In contrast,
high levels of NAAwere found in the brains of many Canavan
disease patients, who lacked the degradative enzyme ASPA,
suggesting that excess NAA levels may have detrimental effects
in the CNS. These findings provided further impetus for
investigators to pursue intensified research into NAA biochem-
istry and the correlations between altered NAA levels and
various neuropathological conditions. Subsequent studies led to
important discoveries as diverse as links between NAA
catabolism and myelin lipid metabolism, and reversible
decreases in brain NAA levels associated with pathologies
ranging from hypoxia to multiple sclerosis.
The most intense research focus on NAA in recent years has
involved MRS-based and magnetic resonance imaging (MRI)-
based analyses of changing NAA levels under numerous
neuropathological and psychopathological conditions. Unfor-
tunately, spectroscopic studies have dramatically outnumbered
studies into the basic biochemistry of NAA in the brain, and this
disparity has complicated the interpretation of MRS results in
various disease states due to the lack of basic knowledge on
NAA function and metabolism. Nonetheless, much important
information on NAA has been garnered by means of
spectroscopic studies.
1.1. Magnetic resonance spectroscopy and imaging of NAA
NAA is unique not only by virtue of its exceptionally high
concentration in the brain, but also due to the powerful signal
that it gives off in water-suppressed proton MRS spectrograms
(Luyten and den Hollander, 1986). The acetate moiety of NAA
is coupled through the amine nitrogen of aspartate (Fig. 1), and
the three equivalent hydrogen atoms of the acetate group
resonate in NMR with a single, sharp peak having a chemical
shift of 2.02 ppm relative to the standard tetramethylsilane.
While the peak at 2.02 ppm is prominently attributable to NAA,
this signal includes smaller contributions from other acetylated
compounds, such as from the neuron-specific dipeptide, N-
acetylaspartylglutamate (NAAG) (Caramanos et al., 2005), N-
acetylneuraminic acid (Varho et al., 1999), and underlying
coupled resonances of glutamate and glutamine. NAAG, the
most concentrated peptide in the brain, may contribute 15–25%
(Pouwels and Frahm, 1997, 1998) to the acetate signal that is
usually ascribed to NAA (Barker et al., 2006), so the reductions
in the NAA peak associated with various brain disorders either
involve coincident reductions in NAAG, or they may under-
estimate the drop in NAA in situations where NAAG levels
remain constant.
Despite technical differences in the methods applied to
acquire localized proton spectra from the human brain on
different MR scanners and at different magnetic field strengths,
the resulting spectra demonstrate substantial visual similarities
from one MR scanner to another and between different brain
regions. MRS reliably quantifies NAA directly from the
number of moles per unit brain volume and can therefore
provide valuable insights into its variations regionally, between
white and gray matter, and in a wide variety of clinical brain
disorders. However, magnetic resonance techniques have
substantial limitations, including the fact that a relatively
large volume of tissue must be sampled to obtain a reliable
signal to noise ratio. This lack of spatial resolution often means
that the signals acquired tend to average metabolite concentra-
tions over gray matter, white matter, and CSF (Barker et al.,
2006). Further, MRS can only detect compounds present at high
concentrations, and therefore most metabolites cannot be
analyzed by these techniques. Despite these limitations, MRS
and MRI provide a great deal of information about several
important metabolites of interest to clinicians and neuroscien-
tists.
In MRS spectra of normal human brain the major peaks
observed from left to right on the spectrogram include myo-
inositol, choline (including glycerophosphocholine, phospho-
choline, and free choline), total creatine (creatine and
phosphocreatine), and NAA (including NAAG) (Fig. 2).
NAA represents the largest peak in spectra of healthy brain
Fig. 2. Representative proton MRS spectrum of normal human brain with
major peaks of interest depicted. Lactate and lipid signals are absent from this
spectrum of a healthy individual. Hunter’s angle (HA; curved gray arrow) refers
to the approximate 458 angle formed by the peaks myo-inositol (mI), creatine
(Cr), choline (Cho), and NAA, when they are present in normal proportions
(NAA/Cr 1.5, Cho/Cr 0.75; mI/Cr 0.5) using short-echo-stimulated echo
acquisition mode (STEAM) spectroscopy. Changes in HA can be applied to
such common MRS diagnoses as tumor (HA < 508), stroke, Alzheimer
disease (HA  158), neonatal hypoxia (HA  458), or AIDS-related progres-
sive multifocal leukomalacia (HA  08). Glx, glutamine and glutamate. Rep-
rinted with permission, NeuroRx (Lin et al., 2005).
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tissue. In pathological conditions ranging from hypoxia to brain
injury, additional peaks are seen representing lipids and lactate.
In practice, while the cerebral concentrations of total creatine
(creatine + phosphocreatine) remain relatively constant,
changes in NAA, either as an absolute concentration or as a
ratio between NAA versus total creatine (NAA/Cr), have
proved diagnostically important. Similarly, increased signals
for lactate and lipid have substantial diagnostic value.
Comparisons of the various MRS and MRI techniques
currently available to neuroscientists and clinicians have been
published (Bammer et al., 2005; Barker et al., 2006; Di
Costanzo et al., 2003). NAA levels measured by MRS have
been shown to be changed in a number of neurological
disorders and conditions. Most of these studies have detected
decreases in NAA concentrations in the affected brain areas,
with the notable exception of Canavan disease which involves
accumulation of NAA throughout the brain (Wittsack et al.,
1996). In earlier studies, the decreases in NAA associated with
various neuropathologies were interpreted to represent irre-
versible loss of neurons. However, accumulating evidence
indicates that these decreases in regional NAA levels can also
represent reversible neuronal or mitochondrial dysfunction
(Bates et al., 1996; Clark, 1998; De Stefano et al., 1995;
Demougeot et al., 2004; Gasparovic et al., 2001; Kalra et al.,
1998; Narayanan et al., 2001). This issue will arise later in the
discussion in a number of contexts.
Reports on conditions other than Canavan disease that result
in raised NAA levels are relatively few. An early investigation
reported that anesthetics and GABA administration caused
NAA levels to increase in rodent brains (Buniatian et al., 1965),
but to our knowledge, these findings have not been confirmed
elsewhere. Two recent reports have shown that NAA levels in
the brain are increased under certain circumstances other than
Canavan disease. First, striatal NAA levels as measured by
MRS were reported to be elevated between 7% and 12% in
children with sickle cell disease (Steen and Ogg, 2005).
Second, administration of the anti-psychotic drug haloperidol
has been reported to elevate NAA levels in the striatum of rats
by 23% as measured by high performance liquid chromato-
graphy (HPLC) (Harte et al., 2005). No changes were observed
in other brain areas. Reports from another group did not support
these results, and instead these researchers detected no changes
in NAA levels in frozen rat brain micro-punches after
haloperidol treatment using HPLC (Bustillo et al., 2004) or
high field MRS (Bustillo et al., 2005). Further studies are
required to determine the effects of haloperidol on brain NAA
levels.
The diseases and disorders in which brain NAA levels are
decreased include brain ischemia, brain injury, brain cancer,
multiple sclerosis and Alzheimer disease, among others
(Danielsen and Ross, 1999). Several chemical treatments have
been reported to reduce brain NAA levels, including a report
that 4 day treatment with ethanol or alcohol dehydrogenase
inhibitors reduced whole brain NAA levels by between 5% and
20% (Baslow et al., 2000). In a subsequent study, 5 day
administration of lithium chloride was reported to reduce whole
brain NAA levels by approximately 13% in the rat model of
Canavan disease (Baslow et al., 2002). Selected MRS studies
detailing changes in brain NAA levels associated with various
conditions are discussed below.
1.1.1. Ischemia and stroke
The current state of knowledge on the use of MRS to analyze
changing NAA levels in experimental ischemia in animals has
been reviewed (Demougeot et al., 2004; Hoehn et al., 2001).
The use of MRS in medical diagnosis of human neurological
disease has also been described (Danielsen and Ross, 1999;
Gillard et al., 2005; Lin et al., 2005). In human and animal
studies, proton MRS and MRI have consistently demonstrated
large increases in lactate levels, and significant decreases in
NAA levels in ischemic brain tissue several hours after onset
(Bruhn et al., 1989b; Di Costanzo et al., 2003; Fenstermacher
and Narayana, 1990; Franke et al., 2000; Graham et al., 1994).
However, there is a paucity of published information
concerning the early response of neuronal NAA metabolism
in human stroke patients. Localized decreases in NAA are seen
within a few hours of ischemic onset in patients with clinical
evidence of stroke, and the levels as measured by MRS are
typically low or absent in chronic infarcts (Gideon et al., 1994;
Gillard et al., 2005). Several key issues concerning spectro-
scopic examination of NAA remain unresolved. These include
the basis of the relatively slow observed decreases in NAA
signal after the onset of stroke, the clinical and functional
correlates of NAA loss, and the issue of whether NAA levels
can recover over time under certain circumstances. To the
extent that satisfactory answers to these issues can be obtained
from animal research, MRS of NAA can profoundly alter the
way we diagnose, monitor and treat human stroke. First we will
examine MRS studies of stroke and hypoxia in humans, and
then wewill explore findings from animal studies of ischemia to
focus on possible mechanisms underlying the neurochemical
changes observed by spectroscopy.
Parsons and coworkers have shown that the ratios of both
NAA to creatine (NAA/Cr) and lactate to creatine (Lac/Cr) are
diagnostic of the long-term outcome in stroke patients (Parsons
et al., 2000).HighLac/Cr ratios (indicating anaerobic glycolysis)
and low NAA/Cr ratios are indicative of poor outcome after
stroke. However, animal and human studies have shown that the
loss of NAA is relatively slow such that NAA levels may be only
partially reduced by the time lactate levels begin to return to
normal (Graham et al., 1993; Petroff et al., 1988). The Lac/Cr
ratio during the subacute phase of stroke in humans has been
particularly useful in determining long-term outcome, and is
more predictive than diffusion weighted imaging of infarct size
alone (Parsons et al., 2000; Walker et al., 2004). Kreis and
colleagues provide evidence from studies after near-drowning
that NAA levels in the human brain respond to hypoxia in a
similar way to that described for animals (Kreis et al., 1996). In
children examined repeatedly with quantitative MRS, T1/2 for
NAA was estimated at about 48 h after near-drowning. Mean
NAAconcentrationswere reduced by 25%after 1–2 days, and by
35–50% after 3–4 days. Five or more days after the hypoxic
insult, NAA levels reached a minimum of about 25% of control.
The degree and the rate of decline ofNAAoccurred considerably
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slower in a predominantly white matter region of the brain than
that described above for a predominantly graymatter region. The
reason for the slower reductions in the concentration of NAA in
white matter remains unknown.
With regard to the parallels between changes in brain NAA
levels as measured by MRS and the clinical outcome in stroke
patients, much anecdotal evidence and a few controlled studies
have equated water suppressed proton MRS measurements of
NAA with neurological outcome. Neurological status on
admission and neurological outcome a few weeks or months
later do indeed correlate with NAA concentration and the ratio
of NAA to creatine/phosphocreatine (NAA/Cr) in gray matter
after near-drowning. The use of NAA as a surrogate for
neuronal cell number and viability, and thus for diagnosis and
prognosis in these clinical settings has been supported by
clinical research (Danielsen and Ross, 1999). Finally, the
question of whether NAA concentrations ever recover is crucial
from the clinical management perspective, since the inter-
pretation of NAA loss as representing neuronal cell death rests
strongly on this premise. Several reports have documented
NAA concentration recovery in gray matter after stroke,
suggesting that some degree of reversible neuronal injury
accompanies ischemia (Walker et al., 2004). Reports of
recovery of NAA in white matter regions are more numerous,
and in MELAS, a metabolically induced regional stroke
characterized by accumulation of lactate and loss of NAA,
recovery of NAA is regarded as the norm (Lin et al., 2003b). In
a recent study of focal ischemia (1 h middle cerebral artery
occlusion) in baboons, Coon et al. showed that lactate was
significantly elevated 3 days and 10 days post-injury, and NAA
was reduced significantly at both time points (Coon et al.,
2006). In less severe injuries encompassing less than 30% of the
affected hemisphere, NAA levels partially normalized by day
10. High lactate levels correlated negatively with functional
outcome, whereas high NAA correlated positively with
functional outcome. In a large study of 71 stroke patients, a
substantial recovery of NAA levels was seen in patients with
small strokes 100 days after the ischemic event (Walker et al.,
2004).
A recent investigation on patients with ischemic injuries in
the region of the middle cerebral artery examined risk factors
associated with stroke, such as age, hypertension and diabetes
to determine if metabolite ratios were affected in contralateral
structures (Walker et al., 2006). These investigators found that
of all the assessed risk factors, only hypertension correlated
significantly with reduced NAA/Choline ratios in the basal
ganglia and periventricular white matter in normal appearing
regions contralateral to the injury. They concluded that
hypertension affects metabolite ratios in normal brain tissue
making MRS measurements after stroke problematic in
hypertensive patients when using contralateral tissue as a
control. These findings highlight the sensitivity of brain NAA to
perturbations, and the ability of MRS to detect these changes,
but also emphasize the many caveats associated with the use of
these techniques to monitor ischemia and other brain injuries.
Animal studies provide a much more detailed picture of the
progression of the pathophysiology associated with stroke and
ischemia, but there are reasons for considering animal models
as imperfect surrogates for studying stroke and hypoxia in
humans. For example, animal models of stroke are done under
highly controlled conditions, and the injuries are relatively
uniform in extent and severity. Further, experimental ischemia
in animals is induced under anesthesia, rather than in
unanesthetized animals, which may affect the outcomes
significantly. In contrast, human stroke is highly heterogeneous
in nature and extent, and occurs under extremely varied
conditions. Nonetheless, experimental models of ischemia have
been very useful in following the evolution of ischemic injury
using MRS, and in confirming the results by independent
methods.
Barker and Gillard have recently summarized evidence from
numerous animal studies showing that the decreases in NAA
occur more slowly than increases in lactate after focal ischemia,
and that larger drops in NAA are seen in the core of the infarct
than in peripheral areas (Barker and Gillard, 2005). There is an
approximate 10% decline in NAA over the first 6–8 h after
occlusive stroke, with a T1/2 of about 15 h for the remaining
50%. The lowest in vivo levels of NAA are observed only after
50–70 h in animal studies (Higuchi et al., 1996; Sager et al.,
1995). Animal studies into the early response to experimental
ischemia have shown that increases in lactate can be observed
by MRS within 40 min of onset, and small decreases in NAA/
Cr were observed at 1 h (Yi et al., 2002). Studies in animals
have demonstrated that the concentration of NAA, as measured
by HPLC, may not always be a good surrogate for neuronal
viability after experimental stroke (Demougeot et al., 2003). In
these studies, NAAwas dramatically reduced in the core infarct
at 3 days (approximately 90%), but was partly recovered after 8
days (approximately 60% of control), and returned to near
normal by 30 days post-ischemia (approximately 90% of
control). Similar findings have been reported in rats subjected
to a 15 min middle cerebral artery occlusion, where NAA/Cr
was decreased significantly at 1 day post-injury, but recovered
to near normal levels 2 weeks after injury (Wang et al., 2006).
Histology showed that the partial recovery of NAA concentra-
tions correlated with strong microglial activation and pro-
liferation in the core of the infarct, suggesting that activated
microglia may be capable of synthesizing NAA (Demougeot
et al., 2003). Large declines in NAA levels associated with
brain ischemia parallel the onset of histopathological events
including dramatically reduced neuronal numbers, reduced cell
size, nuclear pyknosis and infiltration first of polymorpho-
nuclear cells, followed by infiltration of mononuclear cells,
which are most evident between 24 and 48 h in the case of
photochemically induced focal lesions in rats (Lee et al., 1996).
Animal studies of ischemia provide the opportunity to
compare results from MRS with results from other more direct
techniques for measuring NAA levels. Sager and colleagues
have used multiple techniques to study NAA levels and the
levels of other metabolites in experimental ischemic injury in
rodents. HPLC analyses of focal and global ischemia in rats
indicated a slightly more rapid decline in NAA levels in focal
ischemia, reaching approximately 50% of controls in 8 h (Sager
et al., 1995). The most conspicuous difference between focal
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and global ischemia was that aspartate levels decreased in focal
ischemia, but were increased significantly over the course of
24 h after global ischemia, possibly indicating that global
ischemia brings NAA and its degratory enzyme ASPA,
normally segregated in distinct compartments, into contact.
Using MRS, HPLC and microdialysis, Sager and colleagues
showed that MRS and HPLC gave comparable results with
respect to reductions in NAA levels, but that MRS tended to
overestimate NAA concentrations, and underestimate NAA
reductions during ischemia (Sager et al., 1999a). Clearance of
NAA from the extracellular space, as measured by micro-
dialysis, was observed after focal ischemia, but not after global
ischemia. NAA export mechanisms may explain the differences
in NAA loss between focal and global ischemia, where
surrounding intact tissue in focal ischemia is able to remove
NAA to the circulation and maintain a concentration gradient,
whereas globally damaged brain may suffer from compromised
glial clearance mechanisms.
In a subsequent study, Sager and colleagues used standard
histopathological techniques in conjunction with HPLC
analysis of NAA levels and NAA immunohistochemistry to
examine ischemic injury (middle cerebral artery occlusion) in
mice (Sager et al., 2000). NAA declined to 50% and 20% of
control levels in infarcted tissue after 6 and 24 h, respectively,
and no further decrease was observed during the following 6
days. Six hours after ischemic injury, the number of normal-
appearing neurons in infarct-damaged cortical tissue decreased
to 70% of control, and the majority of neurons were
eosinophilic, indicating damage. After 24 h almost no
normal-appearing neurons were seen. The number of eosino-
philic neurons decreased steadily to virtually zero after 7 days.
The number of immunopositive cells staining for standard
neuronal markers within the infarct was progressively reduced,
and after 3–7 days the staining was confined to discrete
granulomatous material in the center of the infarct, which was
infiltrated with macrophages. The central granulomatous
material also stained positively for NAA. NAA levels as
measured by HPLC 7 days after ischemia were still detectable,
remaining between 10% and 20% of controls. Astrocyte
markers progressively increased at the circumference of
infarcted areas, and these areas also showed increased
immunoreactivity against NAA. The authors concluded that
NAA becomes trapped in dying neurons and in cell debris, thus
restricting its use as a marker of neuronal density. There are
reasons for questioning the ‘‘NAA trapping hypothesis’’ as an
adequate explanation for the remaining NAA levels at 7 days
post-ischemic injury. First, it is possible that low levels of NAA
production could be associated with macrophages or reactive
microglia in the infarct and peri-infarct areas under patholo-
gical conditions. Further, other acetylated compounds may
contribute 10% or more to the so-called ‘‘NAA signal’’ inMRS,
and some of these compounds may be more resistant to decline
after injury than NAA (Pouwels and Frahm, 1997; Sager et al.,
2001). Finally, we have observed that the method used to
perform NAA immunohistochemistry (Moffett et al., 1993;
Moffett and Namboodiri, 1995) causes strong, non-specific
antibody binding to damaged brain tissue (unpublished
observations), as was observed by Sager and colleagues in
areas bordering the ischemic injury (Sager et al., 2000).
In order to determine whether NAA levels more closely
parallel neuronal loss in transient global ischemia, where overt
tissue necrosis is avoided, Sager and coworkers studied the loss
of CA1 hippocampal neurons in the two vessel occlusion model
of global ischemia in gerbils (Sager et al., 2001). NAA levels as
measured by single-voxel proton MRS and HPLC correlated
with neuronal loss as determined by histological examination,
with a reported 25% reduction in NAA and complete loss of
CA1 pyramidal neurons 4 days after ischemic injury. The death
of CA1 neurons and the loss of NAAwere comparably slow in
the global ischemia model as compared with the focal model.
NAA could be released from dying neurons and taken up and
excreted to the circulation by remaining, ischemic-resistant
glia. In global ischemia all brain tissue is damaged to some
extent, rather than a specific locus, thus increasing the efflux of
NAA from neurons throughout the brain, while simultaneously
impairing glial clearance.
In summary, despite complicating issues, reducedNAA levels
as detected byMRScanbe an extremely valuablemarker of brain
injury after stroke or hypoxia. In vivo MRS studies support the
hypothesis of NAA as a surrogate for neuronal loss and
dysfunction, and the clinically associated neurological deficits
observed in patients after local or global hypoxia-ischemic
incidents. Outcome predictions based upon residual NAA, and
increased lactate levels in localized proton spectra have proved
rather accurate in such varied ischemia settings as stroke (Barker
and Gillard, 2005; Parsons et al., 2000; Wild et al., 2000),
neonatal hypoxia (Barkovich et al., 1999;Cappellini et al., 2002),
and near-drowning in children (Kreis et al., 1996).
1.1.2. Alzheimer disease
A reasonable working hypothesis, subsequently confirmed
in myriad studies, suggests that regional reductions in NAA
concentration and NAA-creatine ratio are to be found in
individual patients and in patient groups who test positive for
clinical dementia. Patients with Alzheimer disease consistently
show a 15–20% reduction in NAA/Cr (or NAA concentration)
in posterior cingulate gyrus gray matter (Kantarci and Jack,
2003; Moats et al., 1994; Shonk et al., 1995; Waldman et al.,
2002). The gray matter in the region of the posterior cingulate
gyrus has been found to be the most reliable for the diagnosis of
this and other dementias, rather than hippocampus, the region
selected for PET diagnosis, and postmortem histological
examination of Alzheimer disease. In this regard, NAA levels
may reveal something about Alzheimer disease and the
metabolic basis of memory and attention. The finding that
the posterior cingulate gyrus loses NAA early in the disease
supports the notion that this brain region takes part in attention
and memory (Raichle et al., 2001). It has proved technically
more difficult to define significant loss of NAA from the
hippocampus by MRS, the region most implicated in memory,
and involved earliest in plaque deposition as demonstrated by
histopathological studies of Alzheimer disease brain. This does
not argue against existing theory; rather it indicates the
technological limitations of in vivo MRS measurements in the
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temporal lobe. In the hippocampus, a relatively small structure
in the magnetically inhomogeneous environs of the petrous
temporal bone, localized short echo time MRS has measure-
ment errors of 20% or more, sufficient to mask any biological
differences in NAA associated with Alzheimer disease. On the
other hand, use of the more robust MRS technique, long echo
time chemical shift imaging confirms a loss of NAA from the
hippocampus in Alzheimer disease which is directly propor-
tional to the volume loss of that structure (Schuff et al., 2002).
Schuff and colleagues have reported that NAA reductions and
volume loss made independent contributions to the correct
discrimination of Alzheimer disease patients from controls,
with a better than 80% correct diagnosis using NAA declines
alone, which improved to 90% when NAA loss and volume
reductions were combined (Schuff et al., 2006).
In the familial form of Alzheimer disease NAA/Cr is
markedly reduced from the posterior cingulate gyrus (Lin et al.,
2003a), and pre-symptomatic carriers have significantly
reduced NAA/Cr and NAA-myo-inositol (NAA/MI) metabolite
ratios (Godbolt et al., 2006). A precursor of Alzheimer disease
is the recently defined syndrome of mild cognitive impairment.
Evolution to true Alzheimer disease occurs in a sizeable
proportion of these patients and is also accompanied by a
reduction in brain NAA/Cr (Kantarci et al., 2000, 2002, 2003).
Perhaps most instructive in this exploration of a role for NAA in
a disease for which histopathological confirmation is notor-
iously lacking, is the recent MRS data from the well defined
knock-out models of Alzheimer disease in mice (Jack et al.,
2004, 2005). In mice that coexpress mutated forms of human
presinilin-1 and amyloid-b precursor protein, accelerated
amyloid deposition occurs, and the ratios of NAA/Cr, NAA/
MI and glutamate/Cr are decreased with increasing age.
One plausible hypothesis places NAA at the end of the chain
of eventswherein dementia results froma critical reduction in the
number of functioning neuronal units. That couldmean thatNAA
is simply a direct means of measuring neuronal number and
hence quantifying the degree of neurodegeneration. An
alternative hypothesis associates NAAwith neuronal energetics,
suggesting that reduced NAA could simultaneously reflect both
reduced neuronal number, and reduced neuronal energetics in the
remaining neurons. [13C]MRShas been used to demonstrate that
glutamate turnover falls inAlzheimer disease in proportion to the
loss of NAA concentration (Lin et al., 2003a) and that both
glutamate and NAA levels are reduced in the frontal lobes of
Alzheimer mice (Dedeoglu et al., 2004). Human NAA-turnover
rates in the brain as measured by MRS have recently been
published (Harris et al., 2006) offering a glimpse of a role for
NAA metabolism, rather than steady-state concentrations of
NAA in the pathobiology of Alzheimer disease. The rate of
NAA-synthesis, normally about 1% of the Krebs cycle, is
decreased by approximately 60% in Canavan patients
(9.2 + 3.9 nmol/min/g in controls versus 3.6 + 0.1 nmol/min/g
inCanavan disease) (Moreno et al., 2001). In contrast toCanavan
disease where NAA synthesis rates are reduced, NAA synthesis
rates appear to be modestly increased in Alzheimer disease brain
(Harris et al., 2006). If confirmed, this would suggest an adaptive
process which might represent a compensatory upregulation of
NAA synthesis in remaining functional neurons in Alzheimer
disease and perhaps other dementias.
1.1.3. Epilepsy
It has been known since the 1800s that hippocampal damage
is apparent in brain autopsies of epilepsy patients, a condition
known as hippocampal sclerosis. In particular, neuronal loss is
especially apparent in regions CA1, CA3, and the hilus of the
dentate gyrus. Descriptive studies with [1H] MRS in patients
with epilepsy of all types include the observation of focal or
global reductions in NAA signal and NAA/Cr, regardless of
etiology (Briellmann et al., 2005). However, seizures also occur
in many patients with normal NAA concentrations and NAA/
Cr, so that most investigations have explored focal epilepsies,
including post-inflammatory (e.g., Rasmussen’s encephalitis),
post-tumoral and mesial temporal sclerosis induced seizures
(temporal lobe epilepsy or TLE). In all of these, NAA
concentrations are reduced. Perhaps the most challenging
observations come from clinical studies of TLE. While NAA/
Cr is systematically reduced in the affected hemisphere, the
contralateral hemisphere is frequently affected as well
(Vermathen et al., 2002). This certainly complicates the use
of MRS–NAA data as a clinical lateralizing tool for epilepsy
surgeons. But more interesting is the fact that after extirpation
of the damaged tissue from the temporal lobe, NAA recovers
both in the tissue behind the resection, and in the contralateral
hemisphere (Serles et al., 2001). Serles and colleagues suggest
that these post-operative increases in NAA levels may result
from recovery of neuronal metabolism, and possibly increased
dendritic sprouting, synaptogenesis, and neurogenesis. Such
observations, supported by histological and anatomic MRI
evidence, provide convincing evidence of NAA-recovery with
time, and confirm that NAA is responsive to transient neuronal
dysfunction (Briellmann et al., 2005). This aspect of NAA
metabolism will be discussed further in Section 6 below.
1.1.4. Mass lesions including brain cancer
There arefivebasic changes in theMRSsignal associatedwith
brain tumors; NAA is decreased, lactate is increased, lipid is
increased, creatine plus phosphocreatine are decreased, and
choline is increased (Danielsen andRoss, 1999).NAA is reduced
or even absent from most brain tumor spectra, as well as from
most space-occupying brain lesions, whether benign or
malignant (Arnold et al., 1990b; Barker et al., 2006; Bruhn
et al., 1989a;Danielsen andRoss, 1999; Fulhamet al., 1992). The
explanation for the lack of NAA signal lies in the cell lines of
origin for almost all primary and secondary brain tumors, which
do not express the biosynthetic enzyme for NAA, Asp-NAT (see
Section 2.1 below). Interestingly, central neurocytoma (a rare
neuronal tumor accounting for less than 0.5% of CNS tumors)
have been reported by some investigators to exhibit detectable
NAA levels, but reduced NAA/Cr (Chuang et al., 2005;
Jayasundar et al., 2003). Hypothalamic hamartomas are benign
congenital malformations that are disorganized in cytological
architecture, and can contain predominantly glial or neuronal
populations. Amstutz and coworkers have recently shown that
hypothalamic hamartomas exhibit reduced NAA/Cr and
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increased mI/Cr ratios as compared with normal gray matter
(Amstutz et al., 2006). Further, using histological analyses of
these tumors, they show that the NAA signal is greater in
hamartomas with predominantly neuronal content, and lower in
hamartomas with predominantly glial content. This finding
confirms the utility of proton MRS to differentiate tumors with
different cellular populations. One of themost promising uses for
MRS in neuro-oncologymay be to follow the course of recovery
after radiation therapy for glioma, permitting the differentiation
of active glioma from radiation effects in the surrounding tissue
(Fan, 2006).
1.1.5. Multiple sclerosis.
Multiple sclerosis is an autoimmune inflammatory demye-
linating disease of the CNS which links axonal damage to
reduced NAA levels in gray and white matter (Criste and Trapp,
2006). Clinical studies (Bruhn et al., 1992; Davie et al., 1994;
Larsson et al., 1991; Leary et al., 1999) as well as a recent meta-
analysis of the use of MRS in multiple sclerosis (Caramanos
et al., 2005) universally show decreased NAA levels associated
with the progression of the disease. Reduced amounts of NAA
and NAA/Cr in MR-visible lesions and in normal appearing
white matter are readily documented (De Stefano et al., 2001;
Fu et al., 1998; Larsson et al., 1991; Tedeschi et al., 2002). In
this central inflammatory disease, additional MRS changes in
cerebral choline, myoinositol, lactate, and lipid have provided
insights and diagnostic value. With the investigations of Trapp
and colleagues demonstrating transection of axons throughout
the brain of MS patients, these MRS observations are explained
as axonal injury (Criste and Trapp, 2006; Trapp et al., 1998).
NAA also falls in gray matter, perhaps accounting for cognitive
defects often recorded in multiple sclerosis patients (Staffen
et al., 2005). Assays of whole-brain NAA using MRI have
shown that cognitive impairment in multiple sclerosis
correlates with reductions in NAA content (Mathiesen et al.,
2006). While atrophy and loss of NAA are both features of
multiple sclerosis, the degree of loss of whole-brain NAA
exceeds the development of atrophy by several fold, encoura-
ging the conclusion that neuronal dysfunction may precede
tissue loss in multiple sclerosis (Mathiesen et al., 2006). Studies
employing NAA measurements appear to provide a better
correlation with disability in MS patients than do MRI
measures of lesion load (Wolinsky and Narayana, 2002). Other
neurodegenerative diseases such as amyotrophic lateral
sclerosis also show reductions in NAA in affected brain
regions (Kalra and Arnold, 2004, 2006; Rooney et al., 1998),
demonstrating the usefulness of MRS for clinical observations
on the progression of neurodegenerative disorders of all types.
Axonal injury begins early in multiple sclerosis (De Stefano
et al., 2002), and cumulative axon loss results in progressive
disability. However, the disease often goes through phases of
remission and relapse, and white matter plaques visible in
magnetic resonance images can wane with remission of
symptoms. MRS studies show that NAA levels can be
associated with neuronal dysfunction, as well as neuronal
death, because levels have been shown to recover when MRI
visible plaques resolve (Arnold et al., 1990a). Partial recovery
of NAA levels has also been reported after treatment of patients
with interferon beta-1b (Narayanan et al., 2001) glatiramer
acetate (Khan et al., 2005) or fluoxetine (Mostert et al., 2006)
suggesting that NAA levels reflect not only neuronal and axonal
integrity, but also may reflect improvements in neuronal
energetics and possibly remyelination.
1.1.6. Neuro-AIDS and other infections
Human immunodeficiency virus (HIV) infection in and of
itself does not result in reduced NAA levels in the brain, but
many HIV-associated encephalopathies do result in altered
brain metabolite levels, including reduced NAA (Paley et al.,
1996). In addition to AIDS-dementia complex, a condition
which significantly reduces regional concentrations of NAA
(Meyerhoff et al., 1993; Paley et al., 1996; Vion-Dury et al.,
1994), a number of associated conditions stemming from
immune-incompetence also result in local or global reductions
in NAA and NAA/Cr (Schuff et al., 2006). These include
lymphoma, in which the brain spectrum closely resembles that
from other brain neoplasms, and toxoplasmosis, an opportu-
nistic intracellular parasitic infection which reduces all cerebral
metabolite concentrations including NAA (Chinn et al., 1995).
JC-virus induced progressive multifocal leukoencephalopathy
is associated with moderate reductions in NAA, and increased
choline and myo-inositol (Chang et al., 1997). Progressive
multifocal leukoencephalopathy is a fatal demyelinating
disease of the central nervous system that predominantly
affects immunocompromised individuals (Hou and Major,
2000). This CNS viral disease may now be arrested or even
reversed by introduction of effective treatments termed
HAART (highly active anti-retroviral therapy), in which cases,
the decline in cerebral NAA may also be arrested.
Viral encephalopathies including herpes encephalitis (Daniel-
sen and Ross, 1999;Menon et al., 1990), and prion diseases such
as Creutzfeldt-Jakob disease (Oppenheim et al., 2004), result in
reductions in NAA and NAA/Cr over quite large volumes of the
affected brain, and may provide clues as to the nature of the
disease process. In hamsters inoculated with Creutzfeldt-Jakob
disease, large reductions in NAAwere observed in cortex only in
later stages of the disease process (135 days post-inoculation)
(Behar et al., 1998) suggesting that the reductions were
associated with tissue loss. Bacterial and fungal abscesses all
result in local reductions in NAA concentration and NAA/Cr
ratio by the means of tissue destruction (Gujar et al., 2005;
Harada et al., 1994; Kadota et al., 2001; Nakaiso et al., 2002).
1.1.7. Traumatic brain injury
NAA levels as measured by MRS have proven to be a
sensitivemeasure of neuronal compromise after traumatic brain
injury (TBI) (Danielsen and Ross, 1999). Appearances on CT
and MRI scans after TBI, while of great assistance in
management of individual clinical problems, do not always
correlate well with neurological deficit during the acute phase
after brain injury, and give even less guidance on long-term
outcome for patients. In contrast, the use of proton MRS to
determine NAA content locally, and distant to the site of injury,
has proved of considerable value in the clinical setting (Brooks
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et al., 2001) based upon the simplifying hypothesis that in white
matter, loss of NAA defines diffuse axonal injury, and in gray
matter, loss of neurons. However, the heterogeneous nature of
the neuropathological response to trauma has stimulated
interest in other interpretations. In infants subject to ‘‘shaken
baby syndrome’’ loss of NAA appears to follow a cascade of
neurochemical events in which activated phospholipases are
hypothesized to release lipids and macromolecules visible in
the proton brain spectrum (Haseler et al., 1997). Childhood
traumatic brain injury may result in a reversible loss of NAA
which recovers approximately with the time-scale of recovery
from the syndrome of inappropriate anti-diuretic hormone
(SIADH) (Ross et al., 1998). Endocrine response to trauma, in
the form of SIADH, is seen in 40–50% of children with head
injury, and often results in reduced blood and brain osmolytes,
or hyponatremia. Effects of brain hyponatremia are seen in
MRS in the form of decreased myo-inositol, choline, creatine,
and NAA (Danielsen and Ross, 1999). Despite potential
complicating factors such as hyponatremia, MRS measure-
ments of NAA levels in the brain after TBI provide significant
prognostic value relative to long-term outcome, wherein higher
post-injury NAA levels correlate with significantly better
neurological recoveries.
MRS observations in humans after TBI or hypoxia suggest a
time course of hours or days for substantial loss of NAA from
affected brain tissue. However, animal studies of moderate to
severe TBI have shownmore rapid declines inNAA levels which
were paralleled by decreases in ATP levels. Using HPLC
analyses of brain extracts, Signoretti and colleagues reported
significant and concomitant drops in NAA and ATP within
10 min of injury, and partial recovery of both compounds by 5
days in less severe injuries (Signoretti et al., 2001). In more
severe TBI injuries, and those exacerbated by hypoxia-
hypotension, recovery of NAA andATP levels was not observed.
In accord with human MRS studies, the lowest NAA levels
attained after severe TBIwere detected at the longest time period
examined (5 days). These data provide strong support for the idea
that NAA levels are linked to ATP levels, and that both can
recover after injuries that do not involve substantial, permanent
brain tissue destruction. In summary, MRS measurements of
NAA provide an invaluable tool for assessing the degree and
potential recoverability of brain damage following head injury.
1.1.8. Schizophrenia
MRS is capable of detecting both endogenous compounds in
the brain as well as consumed or administered drugs ranging
from anti-cancer agents (Port and Wolf, 2003), to alcohol
ingested in excess (Danielsen and Ross, 1999) to anti-epileptic
medications (e.g., valproic acid) administered in therapeutic
doses (Bluml et al., 2002). Chronic alcoholism is accompanied
by loss of NAA (Jagannathan et al., 1996; Meyerhoff et al.,
2004) which in some studies is reported to recover after
prolonged abstinence (Parks et al., 2002).
In the great majority of neuropsychiatric disorders listed in
DSM-IV 1R, the accepted compendium of clinical psychiatric
diseases, there has been little incontrovertible evidence of
abnormalities in the concentration of NAA in the brain. The
neuropsychiatric condition most studied by MRS is schizo-
phrenia, wherein the majority of published papers report small,
regional reductions in NAA or NAA/Cr (Bertolino et al., 1996;
Callicott et al., 2000a; Deicken et al., 2001). Often the targeted
regions differ fromone study to the next so thatwe obtain no clear
picture of the full extent of the loss or its regional distribution
(Deicken et al., 2000b), and some studies have found no
significant alterations in NAA or NAA/Cr in schizophrenic
patients. A number of groups have reviewed the use of MRS to
analyze alterations in NAA and other metabolites in schizo-
phrenia (Abbott and Bustillo, 2006; Bertolino and Weinberger,
1999;Keshavan et al., 2000;Marenco et al., 2004;Rowland et al.,
2001; Stanley et al., 2000). A recent meta-analysis of MRS
studies on NAA levels in schizophrenia indicated that most
studies did not include enough subjects for substantial statistical
power, but that the majority of studies indicated gray matter
reductions of approximately 5–10% in the frontal lobes (Steen
et al., 2005).A number of studies have found thatNAA levels and
NAA/Cr ratios in the medial temporal lobe and the prefrontal
cortex are reduced in schizophrenia (Abbott and Bustillo, 2006),
and that these reductions parallel alterations in cerebral blood
flow measured with PET and functional MRI (Callicott et al.,
2000b;Marenco et al., 2006a). In a recentMRS study comparing
NAA concentrations in 14 schizophrenics with 13 control
subjects it was found that NAAwas decreased significantly in the
frontal lobe of affected patients (average, 7.94 mmol/L,
compared with healthy subjects average of 8.45 mmol/L,
P < 0.05) (Tanaka et al., 2006). The reduced NAA levels
correlated with the severity of negative symptoms and poor
performance in the Wisconsin Card Sorting Test. Other brain
regions where NAA reductions have been reported in schizo-
phrenia include the thalamus (Deicken et al., 2000a; Ende et al.,
2003; Jakary et al., 2005), anterior cingulate cortex (Deicken
et al., 1997) and the cerebellum (Ende et al., 2005).
Because schizophrenia may be associated with volume
reductions in certain brain regions (Selemon et al., 2002;
Selemon and Goldman-Rakic, 1999; van Haren et al., 2003),
such as the superior temporal gyrus, the medial temporal lobe,
and prefrontal cortex (Shenton et al., 2001), MRS data are
usually normalized for tissue volume (Ohrmann et al., 2006).
Nonetheless, it is difficult to completely separate the issues of
tissue volume and metabolite concentrations as measured by
MRI and MRS, and some differences observed between
schizophrenic patients and controls may have a volume
component. Early signs of schizophrenia have been associated
with reductions in NAA or NAA/Cr. For example, NAA/Cr was
reduced in the left frontal lobe of patients who were considered
at risk for developing schizophrenia, as well as in schizo-
phrenics (Jessen et al., 2006). Wood et al. found that the only
MRS measure which correlated with poor outcome 18 months
after a first psychotic incident in schizophrenia patients was a
lowNAA/Cr ratio detected in the prefrontal cortex (Wood et al.,
2006). Further, reductions in NAA levels in the dorsolateral
prefrontal cortex of schizophrenic patients have been correlated
with poorer performance in the Auditory Verbal Learning Task
(AVLT) indicating connections between cognitive performance
and NAA levels (Ohrmann et al., 2006).
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Intriguing functional correlates of the observed NAA
reductions in schizophrenia have emerged over the last several
years. Ohrmann and coworkers used MRS to show that
glutamate and glutamine levels in the frontal lobes of
schizophrenia patients were reduced in conjunction with the
loss of NAA, suggesting a connection between NAA levels and
glutamatergic neurotransmission (Ohrmann et al., 2005). A
number of studies have found that the expression or activity of
proteins and genes associated with glutamatergic neurotrans-
mission are altered in schizophrenia patients (Moghaddam,
2003; Tsai et al., 1995, 1998). Metabotropic glutamate
receptors are involved in regulating neurotransmitter release,
including the release of glutamate (Cartmell and Schoepp,
2000), and disorders of the NMDA type of glutamate receptor
have been strongly implicated in the etiology of schizophrenia
(Moghaddam and Jackson, 2003). In individuals at risk for
schizophrenia Egan and colleagues found variations in a
particular allele of GRM3, the gene encoding the type 2/3
metabotropic glutamate receptor (mGluR2/3) (Egan et al.,
2004). These GRM3 alleles were associated with reduced levels
of NAA in prefrontal cortex, and reduced expression of a glial
glutamate transporter. MRS studies which examined indivi-
duals with the schizophrenia associated GRM3 allele confirmed
reductions in NAA levels in the right prefrontal cortex
(Marenco et al., 2006b). NAA reductions in prefrontal cortex
have been associated with a dysregulation of dopamine release
in the striatum of schizophrenia patients (Bertolino et al., 2000).
It is interesting to note that NAAG, which is synthesized from
NAA, acts to regulate glutamate and dopamine release, most
likely via activation of presynaptic mGluR2/3 receptors.
Additionalworkwith largergroupswill be required to confirm
and expand these results and determine the full degree and
localization of perturbations in NAA metabolism in schizo-
phrenia patients. Furtherworkwill also be required to ascertain if
NAA metabolic disturbances are etiologically involved in the
developmentof schizophrenia, or are a secondary consequenceof
other factors. Nonetheless, as techniques improve, MRS will
certainly become an invaluable tool in the diagnosis and
treatment of schizophrenia (Abbott and Bustillo, 2006).
It is important to mention before concluding this section that
NAA levels in the brain as measured by MRS, particularly
levels in white matter, have been positively correlated with
general measures of intellectual functioning (Yeo et al., 2006).
In fact, the regions of white matter that were found to correlate
with general measures of intelligence were reported to be
different in the brains of men and women (Jung et al., 2005).
These findings highlight the sensitivity and utility of MRS
techniques for studying normal and pathological brain function
non-invasively, but also raise additional questions concerning
the role of NAA in brain activity and cognition.
1.2. Overview of proposed functions of NAA in the nervous
system
NAA has presented neuroscientists with a particularly
perplexing subject of study in part because application of NAA
to various cell types often does not elicit a detectable response.
Based on a relatively small number of published papers, four
primary hypotheses have been proposed for the role of NAA in
the nervous system. These include: (1) NAA acts as an organic
osmolyte that counters the ‘‘anion deficit’’ in neurons, or a co-
transport substrate for a proposed ‘‘molecular water pump’’ that
removes metabolic water from neurons, (2) NAA is an
immediate precursor for the enzyme-mediated biosynthesis of
the important neuronal dipeptide N-acetylaspartylglutamate
(NAAG), (3) NAA provides a critical source of acetate for
myelin lipid synthesis in oligodendrocytes, and (4) NAA is
involved in facilitating energy metabolism in neuronal
mitochondria.
In addition, a limited number of reports suggest other
possible roles for NAA. In a single study, NAAwas suggested to
form a complex with transfer RNA, which then might be
involved in the initiation of protein synthesis (Clarke et al.,
1975). NAA has also been reported to increase cAMP and
cGMP levels in minced cortical preparations (Burgal et al.,
1982). In another more recent study, NAAwas proposed to be
an endogenous ligand for G protein-coupled metabotropic
glutamate receptors (Yan et al., 2003). In this study, NAA acted
in a dose-dependent manner to induce neuronal depolarization
in dissociated hippocampal neurons, but this finding has not yet
been confirmed in other laboratories. Finally, NAA has been
reported to be present in and released by peritoneal mast cells,
implicating it in possible immune functions (Burlina et al.,
1997). It is interesting to note that NAAG has potent anti-
allergic actions (Bonnet et al., 1985; Chevance and Etievant,
1986; Jambou and Lapalus, 1990; Lapalus et al., 1986;
Miadonna et al., 1998).
It is likely that the list of biological functions served by NAA
will grow with additional research. For further background
information, two previous reviews on the state of knowledge
about NAA are available (Baslow, 2003b; Tsai and Coyle,
1995), and a recent international symposium on NAA has been
published (Moffett et al., 2006).
2. NAA metabolism
2.1. NAA synthesis
Studies on the biosynthesis of NAA had a controversial
beginning. In 1959, Goldstein reported that in the brain NAA is
synthesized through the acetylation of aspartate by a soluble
enzyme, L-aspartate N-acetyltransferase (Asp-NAT; EC
2.3.1.17) (Goldstein, 1959). This result was subsequently
disputed on the grounds of incomplete product identification
and the fact that a membrane bound enzyme was found which
could use acetyl CoA and aspartate to form NAA (Goldstein,
1969; Knizley, 1967). It was then shown that the enzyme that
synthesizes NAA is highly specific to aspartate as the amino
acid substrate, and that it is detectable only in the nervous
system (Benuck and D’Adamo, 1968). A subsequent report
suggested that NAA might be formed by acetylation of tRNA
bound aspartate rather than free aspartate (Clarke et al., 1975),
but this finding was never corroborated. A decade later,
Truckenmiller et al. reexamined the biosynthesis of NAA in the
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nervous system and presented evidence that Asp-NAT is a
membrane bound enzyme which could be solubilized by
treatment with Triton X-100, and they confirmed the earlier
findings that the enzyme is highly specific to aspartate, and that
it is detectable only in the nervous system (Truckenmiller et al.,
1985).
Patel and Clark used another approach to study NAA
biosynthesis (Patel and Clark, 1979). They used isolated rat
brain mitochondrial preparations to show that NAA is
synthesized and exported from mitochondria. Production of
aspartate and acetyl CoA were required for the synthesis of
NAA in these preparations. Aspartate and NAA efflux from
mitochondria were inversely related, such that as NAA efflux
increased, aspartate efflux was reduced. Glutamate and malate
provided sources for aspartate, and pyruvate or 3-hydroxybu-
tyrate served as the sources for acetyl CoA. As expected,
release of aspartate was decreased as the production of NAA
increased under these conditions. Also, the efflux of NAA,
which represents a composite rate of synthesis and efflux, was
much faster in state 3 than in state 4, indicating an apparent
dependence of NAA synthesis on mitochondrial energy state. In
a subsequent study, these authors proposed that NAA is
transported out of mitochondria by a dicarboxylic acid
transporter and that this might be an additional mechanism
to that of citrate for carbon transport from mitochondria to
cytosol (Patel and Clark, 1981).
Asp-NAT has been partially purified from rat brain using
combined chromatographic techniques including size-exclu-
sion chromatography, which showed that the active enzyme is a
high molecular weight protein (670 kDa) with multiple
subunits (Madhavarao et al., 2003). Approximately 95% of
Asp-NAT activity was lost when the enzyme preparation was
treated with 10 mM CHAPS and subjected to size exclusion
chromatography. In contrast, Asp-NATwas stable toward ionic
perturbations as high as 2 M NaCl. The enzyme complex was
confirmed to be very specific to aspartate, with 3% or less
activity toward glutamate, asparagine and aspartylglutamate.
These investigators reported that activity was predominantly
localized in the crude mitochondrial pellet, with only about
10% of the total activity being detectable in the remaining
supernatant. After Percoll gradient centrifugation of the crude
mitochondrial fraction, Asp-NAT activity was found to be
distributed in the pure mitochondrial, synaptosomal and myelin
rich fractions.
A subsequent study by Lu et al. showed that rat brain Asp-
NAT is bimodally distributed in two subcellular fractions, with
approximately three-fold higher total activity (five-fold higher
specific activity) in the microsomal fraction than in highly
purified mitochondria (Lu et al., 2004). Enzyme activity was
not further purified from microsomes to establish which
elements present in that fraction contained Asp-NAT, but
endoplasmic reticulum is a likely candidate for the localization
of enzyme activity. One major difference between this study
and the prior study by Madhavarao and coworkers is in the
distribution of total activity. The study by Madhavarao et al.,
showed about 90% of the total activity in the crude
mitochondrial fraction and about 10% or less in the microsomal
fraction. The study by Lu et al. found approximately 8% Asp-
NAT activity in the purified mitochondrial fraction and about
25% in the microsomal fraction. It is possible that methodo-
logical differences in the subcellular isolation techniques led to
the reported discrepancies in subcellular localization. In view of
the potential implications of microsomal (non-mitochondrial)
Asp-NAT to the functional roles of NAA, this issue requires
further investigation.
Magnetic resonance spectroscopy has provided opportu-
nities to study NAA biosynthesis in broken cell preparations as
well as in tissue extracts following a bolus injection of [1-13C]
glucose into the brain. In extract studies, the water soluble
metabolites are extracted from tissues, and subsequent MRS
measurements of the extracts allow not only identification of
various compounds within the tissue samples, but also
identification of the intramolecular positions of the labeled
atomic nuclei on the basis of their chemical shift. Tyson and
Sutherland have used this approach to study the labeling of
NAA and NAAG after infusion of [1-13C] glucose in rats,
followed by dissection and homogenization of samples from
cerebellum, cerebral cortex and hippocampus (Tyson and
Sutherland, 1998). Their studies showed that label was
incorporated into NAA from labeled acetate (acetyl CoA)
and from labeled aspartate, while NAAG was labeled from
labeled glutamate. In general, incorporation of label into NAA
was slow, whereas incorporation into NAAG through glutamate
was fast, suggesting slow turnover of NAA, and rapid turnover
of NAAG. One finding that was particularly difficult to explain
either by slow turnover rates or isotopic dilution effect was the
fact that they did not see any incorporation of label from either
acetate or aspartate into NAAG over a 200 min infusion period.
Two in vivo [1-13C] glucose studies, one in human and the
other in rat, also have provided interesting results with regard to
NAA synthesis. The human study was done in Canavan disease
patients and corresponding controls. The results showed that
NAA synthesis is decreased by about 60% in the Canavan
disease patients (Moreno et al., 2001). NAA concentrations
were increased by about 50% while aspartate levels were
decreased to a similar extent in these patients. Therefore,
decreased synthesis of NAA in the Canavan patients could have
resulted from limited substrate availability of aspartate or from
product inhibition by NAA, or both. The rat study examined the
relative incorporation label from [1-13C] glucose into the
aspartyl and acetyl groups of NAA (Choi and Gruetter, 2004).
Label incorporation was detected in the acetyl group of NAA
about 1.5 h earlier than in the aspartyl group of NAA reflecting
the delayed labeling of aspartate compared to acetate (acetyl
coenzyme A) from [1-13C] glucose. These investigators
concluded that NAA was present in a single compartment,
that it exhibits relatively low turnover rates (2–3 days for
complete turnover) and that it is not likely to be involved as a
major source of energy when the brain is in a resting state.
2.1.1. NAA localization
In the first report on the distribution of NAA in the brain by
Harris Tallan in 1957, it was found that NAAwas present in the
brains of all vertebrates studied, but the levels in amphibians
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were exceptionally low. Further, it was found that the levels of
NAA in spinal roots, medulla, pons and cerebral white matter
from bovine brain were substantially lower than the concentra-
tions found in cerebral gray matter. This early study has been
cited as the first which demonstrated a neuronal localization of
NAA, but Tallan never proposed a strictly neuronal localization
in this report. Rather, he wrote ‘‘There is a 2-fold difference
between gray and white matter. Acetylaspartic acid is probably
localized in the cells of nervous tissue, inasmuch as analysis of
a sample of human cerebrospinal fluid showed no detectable
amounts of this substance’’ (pp. 42–43). In 1972, Nadler and
Cooper showed that NAA content in glial tumors was much
lower than the levels found in normal brain tissue, and proposed
that NAAwas predominantly localized in neurons, as opposed
to glia (Nadler and Cooper, 1972b).
It was not until the 1990s that specific antibodies to protein-
coupledNAA, includingmonoclonal antibodies (Simmons et al.,
1991) and polyclonal antibodies (Moffett et al., 1991, 1993;
Moffett and Namboodiri, 1995, 2006), permitted the cellular
localization of NAA. These studies demonstrated that NAAwas
present predominantly in neurons and their processes, and that
the levels varied substantially between different neuronal
populations. Immunohistochemical studies on the distribution
of NAA in the rat brain showed notably high levels of NAA in
cortical pyramidal neurons (see Fig. 3), many granule cell
populations throughout the brain, mitral cells of the olfactory
bulb (Simmons et al., 1991), neurons of the olfactory tubercle
(Moffett and Namboodiri, 1995), the dorsal column nuclei and
many neurons throughout the brainstem and spinal cord (Moffett
et al., 1993). Axons in many fiber tracts were moderately stained
Fig. 3. NAA-immunoreactivity in the rat forebrain. (A) Low magnification photomicrograph of NAA staining in the thalamus and hippocampus is shown in (A).
Staining is stronger in most gray matter areas as compared with white matter. Immunoreactivity in the hippocampus is strongest in pyramidal cells, polymorph cells
and granule cells (B). Strong NAA-IR is also observed in cortical areas including retrosplenial granular cortex, where both pyramidal and granule cells are strongly
immunoreactive (C). In neocortex, staining is particularly strong in layer 5 pyramidal cells, such as those in temporal cortex (D) and motor cortex (E). The columnar
organization in these cortical areas can be discerned in NAA-stained sections wherein vertical columns of clustered apical dendrites stained for NAA can be seen (D–
F). For methods, see (Moffett and Namboodiri, 1995). Bar = 600 mm (A), 100 mm (B–E), 50 mm (F).
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for NAA, including the corpus callosum, corticospinal tracts,
optic nerves and tracts, lateral olfactory tracts and stria terminalis
(Moffett and Namboodiri, 1995). HPLC studies have confirmed
the presence ofNAA in optic nerves (Bjartmar et al., 2002). High
levels of NAA have also been observed in cerebellar cortex,
including the Purkinje cell layer, the granule cell layer and the
molecular layer (Simmons et al., 1991).
Based on immunohistochemical findings NAA is present in
most neuronal cell populations, but the intracellular concentra-
tion appears to vary greatly between neuronal groups. For
example, neocortical layer V pyramidal cells typically stain
much more intensely for NAA than do neurons of layer VI, or
neurons in the caudate nucleus (Moffett and Namboodiri,
1995). Immunohistochemical studies confirmed early reports
that NAA concentrations were substantially higher in cerebral
gray matter than in white matter. Further, they confirmed that
NAA did not exhibit a significant concentration gradient along
the rostro-caudal axis of the CNS. No immunocytochemical
electron microscopic studies have been done on the subcellular
localization of NAA, but light microscopic studies suggest that
NAA is found diffusely throughout neuronal cytoplasm, and is
also exceptionally concentrated in small punctate structures
within neuronal cell bodies and basal dendrites, that may
represent clustered neuronal mitochondria (Moffett and
Namboodiri, 1995, 2006).
The neuronal localization of NAA has been confirmed using
HPLC of extracts from various cell types in vitro (Urenjak et al.,
1992). This investigation also found high NAA levels in
immature oligodendrocytes and oligodendrocyte-type 2 astro-
cyte progenitor cells. Similar in vitro findings were reported by
comparing results from HPLC and magnetic resonance
spectroscopy of oligodendrocyte-type 2 astrocyte progenitor
cells and differentiated oligodendrocytes in cell culture
(Bhakoo and Pearce, 2000). They found the highest levels of
NAA in mature oligodendrocytes differentiated with ciliary
neurotrophic factor and in oligodendrocyte-type 2 astrocyte
progenitor cells. Optic nerve transection studies in rats have
shown that NAA levels in the nerves are completely eliminated
24 days post-transection (Bjartmar et al., 2002). In the same
study, retinal ablation on postnatal day 4 suggested that
approximately 20% of the NAA in the optic nerve at day 14, and
5% of the NAA at day 20 was derived from proliferating
oligodendrocyte progenitor cells. In contrast, all NAA in adult
optic nerves appeared to be synthesized exclusively by neurons.
Immunohistochemical studies have indicated very low
levels of NAA immunoreactivity in oligodendrocytes in adult
rats as compared with most neurons (Moffett and Namboodiri,
2006). Developmental studies using anti-NAA antibodies
remain to be done, and no immunohistochemical studies have
been published on the localization of the NAA synthetic
enzyme, Asp-NAT, so it is not known what cell types in brain
express it. However, studies on Asp-NAT enzyme activity in
homogenates of 13 different brain regions showed an increasing
activity gradient from the rostral to the caudal CNS
(Truckenmiller et al., 1985). The highest activity levels were
observed in the medulla, pons, cervical spinal cord, and
midbrain. Lowest activity levels for Asp-NATwere observed in
the retina and amygdala, whereas the pituitary had undetectable
levels. It is interesting to note that the expression of the
neuronal dipeptide NAAG also exhibits an increasing
concentration gradient from the rostral to the caudal CNS.
NAA has not been reported to exhibit such an increasing
concentration gradient (Moffett and Namboodiri, 2006), and in
fact may have an opposite distribution pattern, with higher
levels in forebrain, and lower levels in the hindbrain and spinal
cord of adult animals (Miyake et al., 1981; Tallan, 1957).
2.2. NAA catabolism
The enzyme that catalyzes the deacetylation of NAA is
known as aspartoacylase (ASPA; EC 3.5.1.15), and is also
known by several other names including acylase II and N-
acetyl-L-aspartate amidohydrolase. The enzyme was first
identified in supernatant fractions from hog kidney homo-
genates, and was shown to be very specific for NAA, with little
or no activity toward other acetylated amino acids (Birnbaum
et al., 1952). Another acylase in kidney, acylase I, was found to
be responsible for the deacetylation of other acetylated amino
acids. The ‘‘acylase II’’ enzyme was partially purified and
characterized several years later (Birnbaum, 1955). It would be
nearly two decades before the enzyme was studied in detail
(D’Adamo et al., 1973), and several more years before the
partially purified enzyme was well characterized (D’Adamo
et al., 1977). ASPAwas purified from bovine brain to apparent
homogeneity by Kaul and colleagues, who also showed that it
was expressed at higher levels in white matter than in gray
matter (Kaul et al., 1991). They predicted that the active
enzyme existed as a 58 kDa monomer.
The cloning of the human ASPA gene followed, and the
cDNA predicted an enzyme with 313 amino acids, which
corresponds to a molecular weight of approximately 36 kDa
(Kaul et al., 1993). These investigators also found a common
(85%) missense mutation of the ASPA gene in Canavan disease
patients with an A to C substitution at nucleotide 854. This
mutation was found to reduce ASPA activity to 2.5% of normal
levels,while twoother less commonmutations (C toAmutations
at nucleotides 693 and 914) led to a complete loss of ASPA
activity (Kaul et al., 1994b). Subsequently, a number of
additional mutations in the gene for ASPAwere identified (Kaul
et al., 1996;Zeng et al., 2002). ThemouseASPAgenewas cloned
and expressed in bacteria, with a predicted molecular weight of
approximately 60 kDa on SDS gels, which was thought to be an
overestimation of the actual size of the enzyme, possibly due to
phosphorylation or other influences on gelmobility (Namboodiri
et al., 2000). The deduced amino acid sequence of murine ASPA
is 86% identical to that of human ASPA, and the proposed
catalytic domains are 100% identical (Namboodiri et al., 2000).
Moore and coworkers expressed murine and human ASPA in
bacteria and purified it to homogeneity by anion exchange
chromatography (Moore et al., 2003). The purified enzyme was
found to prefer N-trifluoroacetyl-aspartate over NAA by a factor
of 25-fold, but was very highly specific for aspartate as the amino
acid. Using ESI mass spectroscopy they determined the
molecular weight of the bacterially expressed ASPA to be
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35,171 1 Da, which was thought to differ from the predicted
mass of 35,304 Da due to removal of the N-terminal methionine
in the bacterial expression system.
2.2.1. Cellular ASPA localization
Earlywork on the distribution ofASPAwas done using assays
for enzyme activity, and indicated that it was present in several
tissues, especially CNS, liver and kidney, and that its expression
profile in the CNS followed the time course of postnatal
myelination (D’Adamo et al., 1973). Much later, in vitro studies
in cell culture showed that ASPA enzymatic activity was present
in oligodendrocytes, but not neurons or astrocytes (Baslow et al.,
1999). Bhakoo and colleagues also found ASPA activity to be
expressed in white matter, and the increase in activity during
brain maturation correlated with the time course of myelination
in the rat brain (Bhakoo et al., 2001). These investigators tested
several purified brain cell types in culture and found no ASPA
activity in neurons, and the highest activity in mature
oligodendrocytes (1.749 0.0261 nmol/min/mg protein) and
oligodendrocyte-type 2 (O2A) astrocyte progenitor cells
(2.832 0.785 nmol/min/mg protein). Another research group
reported contradictory findings after measuring ASPA activity
using a sensitive radiometric assay. They showed that primary
cultures of oligodendrocytes exhibited 50–100-fold higher
activity as compared toO2Aprogenitor cells or oligodendrocytes
derived from the O2A progenitor line (Madhavarao et al., 2002).
The reason for the discrepancywithASPAactivity assays inO2A
cells is unclear, and requires further investigation.
In situ hybridization studies further confirmed that ASPA
was present in oligodendrocytes, and that its expression pattern
paralleled that of myelination (Kirmani et al., 2002, 2003).
Immunohistochemical studies using polyclonal antibodies to
ASPA confirmed that it was expressed in oligodendrocytes
(Klugmann et al., 2003). Further, using dual-labeling immu-
nohistochemistry it has been shown that ASPA is definitely
expressed strongly in oligodendrocytes in the CNS, but that it is
not expressed in astrocytes (Madhavarao et al., 2004).
Interestingly, ASPA was also found to be expressed at low
levels in microglia throughout the CNS, as well as in some large
neurons and ascending and descending fiber pathways in the
brainstem and spinal cord. Using the same polyclonal
antibodies, it was also found that ASPA immunoreactivity in
oligodendrocytes in the CNS was not restricted to their
cytoplasm, but was also present in many oligodendrocyte nuclei
(Hershfield et al., 2006; Madhavarao et al., 2004). ASPA
immunoreactivity in the adult rat forebrain is shown in Fig. 4A.
The great majority of oligodendrocytes throughout fiber
pathways such as the corpus callosum strongly express ASPA.
ASPA expression in rat kidney is shown in Fig. 4C, with the
strongest expression being present in kidney proximal tubule
cells.
Immunohistochemical studies often suffer from the possi-
bility that the antibodies might cross-react with similar epitopes
on unrelated proteins. In order to address this possibility with
our polyclonal ASPA antibodies, we tested antibody binding to
brain and kidney tissues from the Tremor rat, an ASPA-null
Fig. 4. ASPA immunoreactivity in normal and Tremormutant rat brain and kidney. A section of rat forebrain stained with anti-ASPA antibodies (1:5000 dilution) is
shown in A, whereas a similar section from a Tremor rat ASPA-null mutant is shown stained with the same antibody in B (1:1000 dilution). In control rat kidney,
ASPA expression was strong in proximal tubule cells (C; 1:5000 dilution), but was not observed in glomeruli (arrows C and D). ASPA immunoreactivity was absent
throughout the Tremor rat kidney (D; 1:2000 antibody dilution), Bar = 120 mm.
J.R. Moffett et al. / Progress in Neurobiology 81 (2007) 89–131102
mutant (Kitada et al., 2000) (see Section 3 below). This mutant
lacks the entire ASPA gene sequence, so no ASPA protein is
produced. Application of the polyclonal ASPA antibodies to
tissues from the Tremor rat demonstrated a complete lack of
staining (Fig. 4B and D). This indicates that the immunor-
eactivity observed in the brains and kidneys of wild type rats
was due to the presence of ASPA gene product or products, and
was not due to cross-reactivity with other proteins.
2.3. NAA and osmoregulation
Tallan noted in his discussion from an early report on NAA:
‘‘Acetylaspartic acid serves to make up part of the anion deficit
known to exist in nervous tissue’’ (p. 44) (Tallan, 1957). He
showed in birds and mammals that NAA accounted for more
than 10% of the total anion content of brain tissue. In the 1960s,
several research groups proposed that NAA might function in
the brain to counter the so-called ‘‘anion deficit’’ in neurons,
based on the high concentrations present (Margolis et al., 1960;
McIntosh and Cooper, 1965). In the 1990s, Taylor and
colleagues proposed that NAA acted as a neuronal osmolyte
involved in either neuronal volume regulation, or acid–base
homeostasis (Taylor et al., 1994). Using microdialysis, they
demonstrated that NAA concentrations in the extracellular fluid
increased in response to hypoosmotic stress (Taylor et al.,
1995). Despite this, the changes in extracellular NAA
concentrations were relatively modest (from 14 to
32 mM) as compared with the substantially larger increases
in extracellular taurine concentrations (from 12 to 80 mM)
under the same hypoosmotic conditions. Similar extracellular
NAA concentration changes were observed using microdialysis
under induced acidosis (Gotoh et al., 1997). Subsequently,
Davies et al. showed that under hypoosmotic conditions
extracellular taurine levels increased almost 20-fold, whereas
extracellular NAA increased by only a few percent (Davies
et al., 1998). As such, NAA may be a minor contributor to
neuronal volume regulation, whereas ions including Na+, K+
and Cl, and metabolites including taurine, glutamate,
glutamine, choline, and myo-inositol provide the predominant
regulation of water homeostasis in the brain (Estevez et al.,
1999; Heilig et al., 1989). It has been noted that NAA is only a
minor contributor to the pool of osmotically active compounds
in the brain which responds to hyperosmolarity or hypoosmo-
larity (Gullans and Verbalis, 1993; Verbalis, 2006).
2.3.1. In vitro MRS studies of NAA responses to osmotic
stress
MRS has been reported to be an accurate method for
measuring brain metabolite concentrations in vitro (Burri et al.,
1990). These methods often employ extraction of solutes from
tissues with perchloric acid, and subsequent analysis of the
recovered metabolites by MRS. One study using MRS to detect
metabolite concentrations in perchloric acid extracts from brain
slices have shown a 60% decrease in NAA concentrations after
hypoosmotic shock (Bothwell et al., 2001). However, there are
several considerations that call these findings into question.
First, these investigators observed much larger changes in NAA
in response to hypoosmotic stress than were seen with taurine.
Microdialysis studies have shown that taurine concentrations
respond more to osmotic changes than have been observed with
NAA (Taylor et al., 1995). Second, such large decreases in
NAA levels after hypoosmotic stress have not been observed
using other methods (Verbalis, 2006). Finally, these investi-
gators reported that the total dissolved species in the brain slices
decreased from 500.6  102.2 to 217.0  60.0 (nmol/mg
protein), or more than half of the solutes measured, a value
that may not be physiologically relevant.
2.3.2. NAA molecular water pump hypothesis
More recently, Baslow and colleagues have proposed a
modified version of the neuronal osmolyte hypothesis in which
NAA acts as a cotransport substrate for a putative molecular
water pump that removes excess metabolic water from neurons
(Baslow, 2002, 2003a; Baslow and Guilfoyle, 2002). The
aspects of NAA that suggest that it could be involved in such a
function include: (1) very high concentration, (2) strong
intraneuronal to extracellular gradient, and (3) the fact that
osmotic stress has been shown to increase the extracellular
concentration of NAA. Despite these arguments, to date no
proteins have been characterized that act to cotransport NAA
and water out of neurons. However, it has been shown that the
sodium-dependent transporter NaDC3 moves extracellular
NAA into glial cells (Ganapathy and Fujita, 2006; George
et al., 2004). In order for the molecular water pump hypothesis
to be verified, a protein or protein complex that cotransports
NAA and water from neurons needs to be identified and
characterized. This issue will be discussed in greater detail in
Section 3.2.
2.3.3. NAA in axon-glial signaling.
NAA has been purported to have an axon-glial signaling
function by some investigators. Based on the localization of the
synthetic and catabolic enzymes for NAA and NAAG, Baslow
has proposed that these compounds and their intermediates,
including acetate, aspartate, and glutamate, are cycled between
neurons and glia as a mechanism of intercellular signaling
(Baslow, 2000b; Baslow and Guilfoyle, 2006). This model
emphasizes the facts that both NAA and NAAG are synthesized
primarily in neurons, but their corresponding catabolic
enzymes are located in oligodendrocytes and astrocytes,
respectively. According to this hypothesis, NAA released from
neurons could signal oligodendrocytes, and NAAG released
from neurons could signal astrocytes. Then NAA and NAAG
would be broken down by the target cells and the catabolites
purportedly cycled back to neurons. This hypothesis assumes
that the breakdown products of NAA and NAAG are passed
from glia back to neurons, and then reutilized for re-synthesis of
both compounds. It is well established that glutamine and
glutamate are recycled between glia and neurons (see Section 7
below), but there is strong evidence that the acetate and
aspartate derived by catalysis of NAA in the brain are not used
for the re-synthesis of NAA (Miller et al., 1996). However, it is
not necessary for the breakdown products of NAA and NAAG
to be re-cycled between glia and neurons in order for these
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compounds to act in a signaling capacity between neurons and
glia. Indeed, other investigators have provided evidence for
axon-glial signaling functions for NAA and NAAG (Ledeen
et al., 2006; Lieberman et al., 2006).
2.4. NAA transporters and clearance
Little is known about the membrane transporters for NAA in
different cell types in the brain, and in tissues such as kidney.
Neurons are the primary producers of NAA in the CNS, and
there are several possible routes for NAA efflux from these
cells. The first is transport of NAA from neurons to
oligodendrocytes, where ASPA removes the acetate moiety
to be used for lipid synthesis (Chakraborty et al., 2001). To our
knowledge, there are no reports that directly demonstrate NAA
uptake by oligodendrocytes, although injection of radiolabeled
NAA into the posterior chamber of the eye clearly shows that
NAA is transported down axons and is passed from neurons to
oligodendrocytes (Chakraborty et al., 2001), suggesting
specific transport mechanisms between these cell types. In
theory, to accomplish this task an export transporter would be
required in the plasma membrane of neurons, and an uptake
transporter like NaDC3 would be similarly required in
oligodendrocytes. In addition to this route of NAA clearance,
extracellular NAA can arise through efflux from neurons along
the steep intraneuronal to extracellular concentration gradient,
or through the enzymatic release of NAA from NAAG by the
action of glutamate carboxypeptidase II on the surface of
astrocytes (Berger et al., 1999; Blakely et al., 1988; Cassidy and
Neale, 1993b; Slusher et al., 1992). Extracellular NAA has been
shown to be preferentially taken up by astrocytes as opposed to
neurons (Sager et al., 1999b) via the dicarboxylate transporter
NaDC3, (Fujita et al., 2005; Ganapathy and Fujita, 2006;
George et al., 2004; Huang et al., 2000), and NAA appears in
urine at low micromolar concentrations, indicating that there is
continuous efflux from the brain (Kelley and Stamas, 1992;
Kvittingen et al., 1986; Miyake et al., 1982). Normal serum
NAA levels are very low, and this may be due to glomerular
filtration in the kidneys (Hagenfeldt et al., 1987). With regard to
NAA clearance, it has been estimated that the human brain
contains approximately 7–8 mmol of NAA, and that normally
about 1% is excreted in the urine per day (Miyake et al., 1982).
In Canavan disease the amount of NAA excreted in the urine
per day is increased to between 3 and 4 mmol, or about half of
the total NAA content of normal brain (Kvittingen et al., 1986).
Increased excretion of NAAG has also been observed in
Canavan patients (Burlina et al., 1994).
There has been some debate as to whether or not astrocytes
express ASPA in vivo, and therefore whether or not they can
deacetylate and metabolize NAA. Some investigators have
found ASPA activity in oligodendrocyte-type 2 astrocyte
progenitor cells (O2A) in culture (Bhakoo and Pearce, 2000).
Fig. 5. NAA immunohistochemistry in rat neocortex. NAA is expressed primarily in neurons throughout the brain, but a relatively small number of endothelial cells
show strong staining (arrows in A). Stained endothelial cells were observed throughout cortex, including parietal cortex (A and B) and temporal cortex (C and D).
Most endothelial cells were unstained for NAA (white holes in tissue, and unstained endothelia in the large vein in A and B). A single endothelial cell in a vein wall is
strongly stained for NAA in (B), whereas the other endothelia are unstained. Staining was stronger in endothelial cell nuclei, as opposed to their cytoplasm (arrows C
and D). Bar = 60 mm (A), 30 mm (B), 15 mm (C and D).
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However, other results have failed to show significant ASPA
activity in O2A cells in culture (Madhavarao et al., 2002), and
immunohistochemical studies have shown a complete lack of
ASPA expression in astrocytes in the brain (Madhavarao et al.,
2004). Considering the facts that astrocytes form a significant
portion of the blood–brain barrier, and that NAA is normally
found in the urine (Hagenfeldt et al., 1987; Kvittingen et al.,
1986), and that astrocytes express a sodium-dependent
transporter for the uptake of extracellular NAA (Fujita et al.,
2005), it seems likely that these glial cells take up extracellular
NAA and excrete it to the circulation. In this regard it is
interesting to note that we have observed NAA-immunor-
eactivity in a sub-population of brain endothelia (Fig. 5). Only a
very small proportion of brain endothelial cells displayed NAA-
immunoreactivity, and the immunoreactivity was more intense
in the nuclei of the cells than in the cytoplasm. Because small
molecules can traverse nuclear pore complexes, it is difficult to
explain the strong nuclear localization of NAA in select brain
endothelial cells. The possible presence of NAA in some brain
endothelial cells requires further investigation.
Together, these findings suggest that in addition to the
neuron to oligodendrocyte transfer of NAA, that there are other
routes of NAA clearance from the brain. One probable route
proceeds from neurons to the extracellular space, followed by
uptake into astrocytes and release to the circulation, and finally
reuptake in the kidney or excretion via urine. This possible
route of NAA clearance from the brain will be discussed further
in Section 7.1.1. Also, because NAA appears at lowmicromolar
levels in cerebrospinal fluid (Faull et al., 1999), this could
represent another route of NAA clearance from brain. Finally, it
is possible that NAA taken up from the extracellular space by
astrocytes could be transferred to oligodendrocytes via specific
gap junctions (connexons) composed of connexins Cx32 and
Cx47 (Menichella et al., 2003; Odermatt et al., 2003).
3. NAA and Canavan disease
A rare leukodystrophy, or spongy degenerative disease
involving brain white matter was described in an infant by
Myrtelle May Moore Canavan in 1931, which she tentatively
identified as Schilder’s disease, or diffuse cerebral sclerosis of
Schilder (Canavan, 1931). This fatal infantile conditionwas later
determined to be a unique autosomal inheritable white matter
degenerative disease by van Bogaert and Bertrand in 1949 (van
Bogaert and Bertrand, 1949). Despite the fact that these
clinicians were the first to correctly identify Canavan disease
as a distinct disorder from Schilder’s sclerosis, the disease is
nonetheless most often referred to as Canavan disease. The
genetic disorder has been designated by other names in the
literature, including ‘‘Canavan–van Bogaert–Bertrand disease’’
and ‘‘spongy degeneration of the brain, van Bogaert–Bertrand
type’’. A number of early reviews on Canavan disease are
available (Adachi et al., 1973; Hogan and Richardson, 1965;
Pratt, 1972). Adachi et al. recognized three forms of Canavan
disease based on time of onset; congenital, infantile and juvenile
(Adachi et al., 1973), however the vast majority of confirmed
cases fit into the infantile category (Matalon et al., 1995).
Infants with Canavan disease appear normal at birth, but
usually show signs of delayed development and decreased
muscle tone (hypotonia), including head lag between 2 and 6
months of age. By one year, macrocephaly is often evident, and
motor development is severely impaired. Infants later develop
optic atrophy, and hypotonicity converts to limb stiffness and
spasticity. The affected children become increasingly debili-
tated with age, often including seizures and an inability to move
voluntarily or swallow. Death typically occurs before adoles-
cence, but some Canavan patients with milder forms survive
into their 20s or beyond.
It was not until the 1980s that the connection between
elevated NAA levels and a progressive demyelinating cerebral
atrophy was discovered. Kvittingen and coworkers first
described a condition of ‘‘N-acetylaspartic aciduria’’ in a
child with progressive cerebral atrophy, wherein the excretion
of NAA was dramatically elevated in the urine (Kvittingen
et al., 1986). They observed demyelination in cerebral CT scans
from the child, and as the child aged they noted cerebral atrophy
and enlarged ventricles. Based on the dramatic increase in
urinary NAA excretion, these authors surmised that this
infantile leukodystrophy might be due to either increased
synthesis or reduced degradation of NAA. Shortly thereafter,N-
acetylaspartic aciduria was identified as being due to a
deficiency of ASPA activity by Hagenfeldt and colleagues, who
found reduced ASPA activity in skin fibroblasts from a child
with severe leukodystrophy. They proposed that the observed
dysmyelination in the CNS was due to a failure of NAA to serve
as an acetate carrier of acetyl groups from mitochondria to
cytoplasm for lipogenesis (Hagenfeldt et al., 1987). Matalon
and colleagues were the first to connect N-acetylaspartic
aciduria and ASPA deficiency specifically to Canavan disease
by showing high NAA levels in urine, and a lack of ASPA
activity in skin fibroblasts in three children with Canavan
disease (Matalon et al., 1988). They proposed three possible
mechanisms whereby a lack of ASPA activity could lead to the
spongy degeneration and dysmyelination observed in Canavan
disease patients. First, because NAA had been shown to be
involved in the production of cerebronic acid (Shigematsu
et al., 1983), Matalon et al. proposed that a defect in
myelination could be responsible for the progression of the
leukodystrophy. Second, they proposed that because aspartate
can act as a neurotransmitter (Bradford and Thomas, 1969), the
lack of deacetylase activity might lead to a disruption of
aspartate neurotransmission, resulting in neurological distur-
bances. Finally, they suggested that high levels of brain NAA
might directly lead to myelin damage and spongy degeneration.
Determining which of these mechanisms were involved in
Canavan disease pathogenesis would require the cloning of the
ASPA gene, and further basic research.
The human ASPA gene was cloned by Kaul and colleagues
in 1993, as discussed above (Section 2.2) (Kaul et al., 1993).
Once Canavan disease was determined to be a specific
autosomal recessive genetic disorder, it was assigned a
Mendelian Inheritance in Man (MIM) number (Hamosh
et al., 2005) with the designation of #271900. Early genetic
studies found that two mutations were prevalent among
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Ashkenazi Jewish patients with Canavan disease (Kaul et al.,
1994a). A missense mutation at codon 285 resulted in a
substitution of glutamate to alanine, and was found to account
for 83.6% mutations identified in 104 alleles from 52 unrelated
Ashkenazi Jewish patients. A nonsense mutation was found in
13.4% of the alleles from Jewish patients at codon 231, which
converts tyrosine to a stop codon. The incidence of mutations in
the ASPA gene are far less common in non-Jewish patients, and
the mutations are distinct, and more diverse (Kaul et al., 1996;
Sistermans et al., 2000). The most prevalent non-Jewish
mutation was identified in codon 305, a missense mutation
substituting alanine for glutamic acid. This mutation was
observed in 35.7% of the 70 alleles from 35 unrelated non-
Jewish patients (Kaul et al., 1994a,b). Fifteen other mutations
were detected in 24 other Canavan disease patients. Recently
additional mutations have been reported, in some cases with the
children dying immediately after birth (Zeng et al., 2002). The
diverse number of mutations associated with Canavan disease
limits the usefulness of DNA analyses for prenatal diagnosis in
non-Jewish parents. However, preimplantation genetic diag-
nosis has recently been successfully employed to screen in vitro
embryos from Ashkenazi Jewish parents prior to implantation
(Yaron et al., 2005).
Two animal models of Canavan disease exist (see Section
3.3 below); the so-called Tremor rat (Serikawa et al., 1987) and
the ASPA knockout mouse (Matalon et al., 2000). The Tremor
rat model is a stable line developed from a naturally occurring
mutant with a genomic deletion on chromosome 11 spanning 4
genes, including the aspartoacylase gene, olfactory receptor
gene, vanilloid receptor subtype I gene, and the calcium/
calmodulin-dependent protein kinase IV gene (Kitada et al.,
2000). The Tremor rat shows no ASPA activity in brain, and
greatly reduced activity in kidney, and also exhibits increased
brain NAA levels (Kitada et al., 2000). Tremor rats exhibit
muscular tremors starting at about 2 weeks of age, which give
way to absence-like seizure activity in later development.
Pathology in the CNS involves white matter spongiform
degeneration and hypomyelination (Kondo et al., 1991).
Similarly, homozygous ASPA / knockout mice exhibit
subcortical and white matter vacuolation. In addition, they fail
to thrive, exhibit macrocephaly, display tremors, and some
develop seizures by 6 months of age (Matalon et al., 2000).
Homozygous ASPA / mice lack detectable ASPA activity,
and show impaired motor activity as well as a nine-fold increase
in NAA levels in urine as compared with control mice. Because
ASPA is strongly expressed in kidney proximal tubule cells it
might be expected that ASPA deficiency would result in kidney
pathologies, but this does not appear to be the case, as reports of
Canavan disease patients or ASPA-deficient animals do not
make note of observable kidney damage or disease.
Despite the great deal of work done over the last five decades
to understand this fatal inheritable CNS leukodystrophy, there
is still controversy over the specific etiology resulting in
progressive white matter disease and subcortical vacuolation.
Experimental and clinical attempts to halt or reverse the
pathogenesis of Canavan disease will be discussed below (see
Sections 3.3 and 3.4).
3.1. NAA neurotoxicity
An unresolved issue concerning NAA involves its potential
toxicity to neurons or oligodendrocytes when the concentration
is substantially elevated in the brain, as in the case in Canavan
disease (Kitada et al., 2000; Leone et al., 1999). Despite the
established connection betweenmutations in the gene for ASPA
in Canavan disease, and the lost capacity to deacetylate NAA,
the specific connection between ASPA deficiency and the
failure of proper CNS development remains controversial
(Matalon et al., 1995; Matalon and Michals-Matalon, 1998). It
has been proposed that lack of deacetylase activity against
NAA leads to toxic increases in the concentration of NAA in the
brain (Akimitsu et al., 2000; Kitada et al., 2000; Leone et al.,
1999, 2000). The level of extracellular NAA may be a critical
factor in determining if it has toxic effects. Pliss and colleagues
reported that injection of 0.25 mmol of NAA into the lateral
cerebral ventricles of rats did not induce any detectable
neuronal death in the hippocampus, (Pliss et al., 2003) whereas
Akimitsu et al. reported that injection of 8 mmol of NAA into
the lateral ventricle of rats induced strong seizures (Akimitsu
et al., 2000). However, these same investigators observed no
effects after injecting 2 mmol of NAA into the lateral ventricles
of normal rats (Kitada et al., 2000). Seizures are one of the
symptoms of late stage Canavan disease, but it has not been
conclusively shown that elevated NAA levels are responsible
for the seizure activity. Akimitsu and colleagues used
exceptionally high concentrations of NAA (0.5–1 M) to
elicit seizure activity, so there is some question about
physiological relevance to Canavan disease, where the
concentration may be elevated no more than two-fold (Kitada
et al., 2000). This translates to approximately 15–25 mM,
which is far below the 500 mM to 1 M concentrations injected
by Akimitsu and colleagues to induce seizures in rats.
Using organotypic hippocampal slice preparations, Tran-
berg and colleagues showed that the addition of 10 mMNAA to
the culture medium had no effect on increasing cell death after
24 h, indicating that NAA is not toxic to neurons or glia at
extracellular concentrations far higher than normal (Tranberg
et al., 2004). The potential toxic or excitotoxic actions of NAA
have not been fully explored, but the evidence suggests that
high levels of NAA in the brains of Canavan disease patients
may be involved in some aspects of the pathogenesis, possibly
by inducing seizure activity. However, it is also possible that the
observed hypomyelination could also lead to seizure activity by
way of disrupting normal neurotransmission.
3.2. NAA-related osmotic/hydrostatic pressure in Canavan
disease
Awell-cited hypothesis concerning the etiology of Canavan
disease is that the lack of deacetylase activity against NAA
leads to osmotic dysregulation in the brain, which then results
in a buildup of NAA-associated water in the extracellular fluid,
resulting in the dysmyelination and subcortical vacuolation
observed in Canavan patients (Baslow, 2000a, 2002, 2003a,b;
Baslow and Guilfoyle, 2006). Currently to our knowledge,
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there is no direct evidence that has shown that excess NAA in
the brain causes dysmyelination through osmotic damage, but
nonetheless, this hypothesis is often invoked in discussions of
the pathogenesis of Canavan disease. The osmotic damage
hypothesis of Canavan disease may have had its origins in work
on osmoregulation in ocular tissues of fish (Baslow and
Yamada, 1997). N-acetylhistidine is present at high concentra-
tions in the lens of poikilotherms including fish, and Baslow
proposed that it could be involved in tissue fluid balance
(Baslow, 1997). It was also proposed that what appeared to be
an inverse phylogenetic relationship between the concentra-
tions of NAA and N-acetylhistidine in brain, eye and other
tissues might indicate that they served similar membrane
transport or fluid balance functions in different physiological
contexts. Baslow proposed that the synthetic and hydrolytic
compartments for NAA and N-acetylhistidine were distinct and
involved a cellular or fluid boundary, and therefore the two
compounds served similar transport or fluid balance functions
in different organisms.
Based on subsequent studies with 14C-isotopes and excised
lens from goldfish, Baslow proposed that N-acetylhistidine
acted as a ‘‘molecular water pump’’ in which the solute flowed
down its concentration gradient through calcium channels, and
removed 33 mmol of water per millimole of N-acetylhistidine
against a water gradient (Baslow, 1998). Further, he proposed
that the N-acetylhistidine molecular water pump was an
archetype for similar molecular water pump systems in derived
vertebrates, including NAA synthesis, transport and breakdown
in the brains of birds and mammals. This molecular water pump
hypothesis was elaborated in later publications, wherein
Baslow proposed that NAA is a significant neuronal osmolyte
and that the inability to deacetylate NAA in oligodendrocytes
leads to increased osmotic pressure in the intracellular space
between axons and their myelin ensheathment, leading to the
intramyelinic splitting and intralamellar edema observed in
Canavan disease (Baslow, 1999, 2000a). Baslow and Guilfoyle
used magnetic resonance spectroscopy of samples of NAA in
water to estimate the degree of hydration of NAA in order to
determine the degree to which NAA could transport water
across neuronal membranes (Baslow and Guilfoyle, 2002).
They calculated a hydration factor of 32:1 for NAA, and
suggested that NAA was a good candidate for a neuronal
osmolyte which acted in concert with a transport protein as a
molecular water pump.
Baslow outlined the criteria for meeting the status of a so-
called molecular water pump. ‘‘In theory many solutes could be
used for this purpose as long as certain conditions were met.
These conditions include the requirement for a suitable
cotransporter protein with associated gate and trigger
mechanism for regulation of solute transport, a method for
cycling the solute by means of which its intercompartmental
gradient can be continuously reestablished, and a coupled
energy source’’ (Baslow, 1999) (p. 89). Currently, NAA does
not meet all of these criteria for molecular water pump status,
including the fact that no cotransport protein has been
identified, and there is only scant evidence on possible gating
mechanisms that specifically regulate NAA release from
neurons. Results with organotypic hippocampal slices have
been instrumental in demonstrating that NAA is not released
under hyper-osmotic conditions, but that it is released in a
calcium-dependent manner upon stimulation of neuronal
NMDA receptors (Tranberg et al., 2004). NAA release in this
systemwas not stimulated by potassium depolarization, but was
prolonged for 20 min after a 5 min application of 60 mM
NMDA. The authors noted that the efflux was specific to
selected organic ions, including NAA, taurine, glutathione and
phosphoethanolamine, but they did not propose a physiological
role for the regulated release. Receptor-meditated, calcium-
dependent release of NAA from neurons has not been reported
by other research groups, but if confirmed, these findings
suggest that glutamatergic neuronal activity is linked to NAA
efflux from neurons, and that this may be a regulated
physiological process (see Section 7.1.1 below).
Many different mechanisms are involved in brain water
regulation, and cotransport associated with the active or passive
movements of various solutes into or out of neurons is one key
factor. As such, the solutes that are most actively redistributed
in response to osmotic stress must be the same hydrated solutes
involved in moving water into and out of neurons. As
mentioned above (Section 2.3) the major solutes that are
redistributed in response to osmotic stress in the brain include
glutamine, glutamate, taurine, choline and myo-inositol
(Verbalis, 2006). For this reason, it seems likely that NAA is
only a minor contributor to the osmotically active pool of
solutes present in neurons that can respond to changes in
osmolarity. Finally, until an osmotically sensitive NAA export
protein is found in neurons, the NAA molecular water pump
hypothesis remains speculative.
3.3. Gene transfer therapy for Canavan disease
Founded on the assumption that the primary etiology of
Canavan disease involves toxic NAA concentration increases in
the brain (Leone et al., 1999), possibly causing osmotic
dysregulation and intramyelinic water accumulation, adeno-
viral transfer of the ASPA gene to the brains of humans has
been performed in an to attempt to reverse brain edema and
vacuolation (Janson et al., 2002; Leone et al., 2000). No follow
up studies showing significant myelination or motor improve-
ments in these children have been published to date, so it is
difficult to assess to what extent any pathologies were
ameliorated. However, a number of studies have been done
using the ASPA-null mutant Tremor rat (see Section 3 above),
and the ASPA/ knockout mouse model of Canavan disease,
and these studies have yielded somewhat conflicting results
with regard to the efficacy of this approach.
The Tremor rat has been proposed to be an animal model for
petit mal seizures due to the fact that the rats exhibit so-called
absence-like seizures, which are characterized by sudden
immobility, with the coincident appearance of 5–7 Hz spike–
wave-like complexes in cortical and hippocampal electro-
encephalograms (Seki et al., 2002; Serikawa et al., 1987). The
Tremor rat ASPA gene transfer studies that have been done in
the last several years have made use of adenoviral gene vectors
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to deliver the ASPA gene to the brain. The investigations by
Seki and colleagues involved delivery of replication-deficient
recombinant adenoviral gene vectors containing the ASPA gene
into the lateral cerebral ventricles, which was reported to
primarily induce expression in ependymal cells of the ventricle
lining (Seki et al., 2002, 2004). These two studies were done on
different mutant rat strains, both of which lacked the gene for
ASPA, and which display absence-like seizures. In both studies,
a very transient reduction in seizure activity was noted at 1
week after gene transfer, but this effect was not maintained by
10 days after transfer, and no improvement in animal survival
rates was observed. The authors noted that the viral vector they
employed induced immune system responses which may have
interfered with the efficacy of the treatment.
The most recent adenoviral gene transfer studies employed
improved gene transfer technology using the recombinant
adeno-associated virus serotype 2 vector (AAV-2) (Klugmann
et al., 2005; McPhee et al., 2005). In one of these gene transfer
studies in Tremor rats, NAA levels were reduced, and seizure
activity was diminished, but brain vacuolation and dysmyelina-
tion were unaffected, suggesting that these pathological
features of the disease are not mediated by excessive NAA
concentrations (Klugmann et al., 2005). More importantly, no
motor improvements were observed in the Tremor rats after
gene transfer. In the other study, reduced NAA levels and
somewhat improved motor functions were reported (McPhee
et al., 2005). However, motor improvements were modest, and
statistical significance in motor performance improvement was
determined between Tremor rats which had received adeno-
virally transferred green fluorescent protein gene, versus
Tremor rats which had received adenovirally transferred ASPA
gene. Statistical significance between naı¨ve (no gene transfer)
Tremor rats and those that received adenovirally transferred
ASPA was not reported. Because Tremor rats with green
fluorescent protein gene transfer performed more poorly on the
motor tests than the naı¨ve Tremor rats, the significance of the
reported improvements in motor function may be questionable.
An ASPA / knockout mouse Canavan disease model has
been developed (Matalon et al., 2000), but somewhat less work
has been done with this model to date. A single reported trial of
recombinant AAV–ASPA treatment has been attempted with
this model (Matalon et al., 2003). In that study, recombinant
AAV–ASPA gene transfer provided excellent ASPA expression
and activity in and around vector injection sites, and reduced
NAA levels as detected by magnetic resonance spectroscopy.
Further, histopathological examinations revealed locally
reduced brain vacuolation, particularly in thalamus, in animals
that received AAV–ASPA. In spite of the histopathological
improvements, no improvements in motor performance, brain
myelination or development were reported after ASPA gene
transfer in ASPA / mice.
A potential problem with gene transfer therapy for ASPA
deficiency is that current technology is limited by the available
vectors for introducing genes into different brain cell
populations. ASPA is present in the brain primarily in
oligodendrocytes, but NAA is produced primarily in neurons,
so the anabolic and catabolic compartments are distinct.
Adenoviral gene transfer (AAV-2) involves the use of a
neurotrophic viral vector to deliver a specific expression
cassette to target cells, and it was shown that the majority of
cells which expressed delivered genes were neuronal (McPhee
et al., 2005). As such, the segregation of the NAA synthetic and
degradative compartments was not restored by gene therapy.
This inability to direct the vector to oligodendrocytes may limit
the usefulness of ASPA gene therapy until vectors which target
other cell types in the brain are developed. While gene therapy
is a very promising technique, the technologies necessary for
proper integration of selected genes into the correct cell
populations in the brain remain to be developed, and additional
basic research is required.
3.4. Potential acetate supplementation therapy for
Canavan disease
Based on the idea that the loss of ability to metabolize NAA
in the catabolic oligodendrocyte compartment of NAA
metabolism results in intramyelinic osmotic damage, Baslow
concluded that the etiology of Canavan disease does not involve
an inability of oligodendrocytes to produce myelin (Baslow,
2000a). He stated his conclusion: ‘‘The demyelination in CD
[Canavan disease] is probably not owing to the inability of
oligodendrocytes to produce myelin, but to the continuous
destruction of myelinating oligodendrocytes themselves by the
NAA osmotic pressure generated in the sealed paranodal and
the internodal regions’’ (p. 67). However, based upon a growing
body of evidence connecting NAA-derived acetate to aspects of
myelin lipid formation (Chakraborty et al., 2001; D’Adamo
et al., 1968; D’Adamo and Yatsu, 1966), we and others have
proposed that the primary etiological mechanism in the
pathogenesis of Canavan disease is reduced lipid synthesis
due to a reduced supply of NAA-derived acetate in the brain
during myelination (Hagenfeldt et al., 1987; Madhavarao et al.,
2005; Mehta and Namboodiri, 1995) (see Section 5 below).
ASPA acts to remove acetate from NAA in oligodendro-
cytes, and therefore ASPA activity against NAA would be
expected to increase free acetate levels in these cells. A loss of
ASPA enzyme function during postnatal myelination could
then lead to an acetate deficiency in oligodendrocytes. Because
acetate in the form of acetyl coenzyme A is a key building block
of lipids, a lack of ASPA activity in oligodendrocytes could
theoretically limit lipid synthesis in the myelinating cells of the
brain when axonal myelination is maximal during early
infancy. In this regard, we have observed an approximately 80%
reduction in free acetate levels in the brains of ASPA/mice
at the time of peak myelination (Madhavarao et al., 2005). For
these reasons we have proposed dietary acetate supplementa-
tion therapy, for example with glyceryl triacetate (GTA), as a
possible treatment for Canavan disease (Madhavarao et al.,
2005; Mathew et al., 2005; Mehta and Namboodiri, 1995;
Namboodiri et al., 2006b).
GTA is a triester with three acetate groups coupled to
glycerol. Esterases present in most tissues of the body can
cleave the acetate moieties, generating free acetate. Dosing
experiments in mice demonstrated that GTA was 10–20 times
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more effective at delivering acetate to the brain than calcium
acetate, and that it was well tolerated by developing mice
(Mathew et al., 2005). If substantially elevated levels of acetate
can be maintained in oligodendrocytes through dietary acetate
supplementation during postnatal myelination, this should
theoretically correct the acetate deficiency that occurs in
Canavan disease. It is likely that acetate supplementation of
Canavan patients would have to be initiated within the first few
months after birth in order to ensure that critical neurodevelop-
mental stages requiring myelination are accomplished on
schedule, including visual system development. Other potential
problems would not be addressed by acetate supplementation
including excess NAA concentrations in the brain, reduced
aspartate levels in oligodendrocytes, and possibly reduced
neuronal respiration on glutamate due to product inhibition of
the mitochondrial enzymes Asp-NAT and aspartate amino-
transferase (see Section 6.3 below). If these turn out to
contribute significantly to the pathogenesis of Canavan disease,
then acetate supplementation therapy may only be partially
effective as a treatment.
In a collaborative study between the Namboodiri and
Matalon laboratories, preliminary results have been obtained
with a relatively small number of ASPA / mice
supplemented with GTA in the diet. The results indicate
reduced vacuolization and reduced water content in the brain,
improved motor function, increased lipid content and reduced
mortality in homozygous ASPA / mice treated with GTA
(unpublished observations). Because of the small numbers of
treated mice, these results should be considered preliminary,
and more conclusive data with a larger number of mice will be
needed in order to find out whether GTA supplementation can
prevent the severe phenotype associated with ASPA deficiency.
Breeding ASPA / mice and Tremor rats is difficult
because heterozygote breeding pairs are required, which
produce litters averaging only 25% ASPA / pups, and
because the affected animals do not thrive and often die soon
after birth. As such, many breeding cycles are required to obtain
sufficient numbers of ASPA deficient pups. We are planning
studies with GTA supplementation on a greater number of
homozygous animals so the efficacy of acetate can be
determined more conclusively as a therapeutic agent for the
treatment of Canavan disease.
4. NAA and NAAG biosynthesis
NAAG is the most concentrated neuropeptide in the human
brain. It is synthesized enzymatically from NAA and glutamate
(Arun et al., 2006; Boltshauser et al., 2004; Cangro et al., 1987;
Gehl et al., 2004) and is localized in specific types of neurons
throughout the CNS (Anderson et al., 1987;Moffett et al., 1993;
Moffett and Namboodiri, 1995, 2006; Tieman et al., 1991;
Tieman and Tieman, 1996). NAAG is released from synapses in
a calcium dependent manner (Williamson et al., 1991), and acts
through presynaptic metabotropic glutamate receptors to
modulate the release of classical neurotransmitters (Xi et al.,
2002; Zhao et al., 2001). NAAG biosynthesis has been studied
for over three decades, but the biosynthetic and regulatory
mechanisms involved remain poorly understood. To date, no
NAAG biosynthetic enzyme has been isolated or characterized,
and synthesis from radiolabeled precursors has only been
demonstrated reliably in tissue explants and cell culture with
intact cells. The primary reason that a NAAG biosynthetic
enzyme has not been identified is due to the lack of ability to
detect synthesis in tissue or cell homogenates, except for a few
early reports that have not subsequently been corroborated
(Reichelt et al., 1976; Reichelt and Kvamme, 1973).
The subsequent inability of other research groups to
demonstrate enzymatic NAAG biosynthesis in brain tissue
homogenates is a well known but under-reported fact in NAAG
research. The loss of NAAG synthesis upon homogenization of
tissues or cultured cells could have many possible explanations.
These include the sequestration of a putative NAAG
synthesizing enzyme or enzyme complex in a membrane
compartment where optimal conditions for enzyme activity are
maintained. Homogenization of cells or tissues leads to the
mixing of extracellular and intracellular constituents, the
release of proteases and peptidases, and the elimination of
subcellular compartmentation and transmembrane gradients,
all of which could adversely affect NAAG synthesis.
Homogenization could expose a NAAG synthetase enzyme
to inhibitory compounds that render it inactive. It is also
possible that intact neuronal bioenergetic systems link NAAG
synthesis to ATP hydrolysis, whereby homogenization inter-
rupts an energy-dependent reaction. Another possibility is that
NAAG synthetase is degraded very rapidly after synthesis, and
has a very short functional half-life after homogenization. The
inability to detect any NAAG synthesis from radiolabeled
precursors in brain homogenates prevents further purification,
identification and characterization of the enzyme or enzymes
responsible. However, indirect means of examining some of the
basic properties of a NAAG synthetase enzyme have been
brought to bear in several different preparations as outlined
below.
4.1. Evidence for a NAAG synthetase enzyme
The prevailing hypothesis is that NAAG is synthesized by
the enzymatic ligation of NAA and glutamate, possibly by an
energy-requiring process. The presence of a ‘‘NAAG synthe-
tase’’ enzyme has been postulated based on indirect means in
several studies (Arun et al., 2006; Cangro et al., 1987; Gehl
et al., 2004; Urazaev et al., 2001; Williamson and Neale, 1988).
Most recent studies which have successfully demonstrated
NAAG biosynthesis were done in neural explants, including
excised rat dorsal root ganglia (Cangro et al., 1987), excised
frog retinas (Williamson and Neale, 1988), crayfish nerve cord
(Urazaev et al., 2001) and hemisected rat spinal cord (Gehl
et al., 2004). In several recent reports, NAAG biosynthesis has
been observed in cell culture, including primary rat astrocyte
cell culture (Gehl et al., 2004), and in a continuous human
neuroblastoma cell line (Arun et al., 2004, 2006).
The first convincing studies on NAAG biosynthesis were
conducted by Cangro and colleagues using excised rat dorsal
root ganglia (DRG) in short-term culture (Cangro et al., 1987).
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They incubated DRG in tissue culture for 3 h with radiolabeled
glutamine, and found very low levels of incorporation into
NAAG during that time frame. Interestingly, with this short
time course 3H-glutamine was the best precursor, whereas
glutamate was incorporated at less than half the rate. For
reasons that are not understood, radiolabeled aspartate was not
incorporated into NAAG during the 3 h incubation period. The
identity of the newly synthesized NAAG was confirmed by use
of multiple chromatographic techniques in sequence, including
cation exchange, anion exchange and reverse phase HPLC.
Such corroboration is critical to ensure correct product
identification because a number of closely spaced radiolabeled
peaks are observed on anion exchange HPLC chromatograms
from NAAG labeling experiments.
Williamson and Neale studied NAAG biosynthesis in frog
retinas in vivo by injecting 50 mCi of 3H-glutamate into the eye,
waiting 18 h, injecting again, and waiting another 6 h before
extracting the retinas (Williamson and Neale, 1988). With these
long incubation times and high doses of radiolabel they found
significant incorporation of glutamate into NAAG. These same
investigators were not able to demonstrate the incorporation of
radiolabeled precursors into NAAG in a chick retina prepara-
tion in vitro (Williamson and Neale, 1992). In those
experiments radiolabeled NAAG was taken up robustly and
released in a calcium dependent manner, but no significant
incorporation into NAAG was seen with tritiated glutamine,
glutamate or aspartate. However, it should be noted that for
these experiments the investigators incubated retinal explants
with only 5 mCi/ml radiolabeled precursors for 1 h before
determining the level of incorporation into NAAG, which may
not have been long enough to synthesize detectable quantities
of NAAG.
More recently, Neale and colleagues incubated hemisected
spinal cords with 10 mCi of tritiated precursors (final
concentrations: [3H]-Glu, 426 nM; [3H]-Gln, 400 nM; [3H]-
Asp, 540 nM; or [3H]-NAA, 540 nM). Under these conditions,
the earliest time point where NAAG synthesis could be detected
was after a 90 min incubation with radiolabeled glutamine
(Gehl et al., 2004). It would require at minimum that two
enzymes convert glutamine and NAA into NAAG, including
the conversion of glutamine to glutamate by glutaminase, and
then the ligation of NAA to the newly synthesized glutamate.
The reported time frame of 90 min is highly suggestive of a
direct enzymatic route to NAAG biosynthesis. However, as
with other studies using tissue explants, extremely low
incorporation rates were obtained. The authors cited the
fragility of the explanted spinal cord tissue as a reason for the
low incorporation rates.
4.1.1. NAAG biosynthesis and protein synthesis inhibition
Inhibitors of protein synthesis have been reported to have no
effect on the incorporation of radiolabeled precursors into
NAAG in neural explants (Cangro et al., 1987; Gehl et al.,
2004), suggesting that NAAG is not synthesized on ribosomes
as a portion of a protein, and then cleaved to generate the active
molecule as is the case with many other bioactive peptides. The
first reliable report of NAAG biosynthesis in tissue explants
demonstrated that incubation of excised rat dorsal root ganglia
with cycloheximide or ansinomycin at 200 mM did not inhibit
incorporation of radiolabel into the dipeptide (Cangro et al.,
1987). In this report, the addition of protein synthesis inhibitors
actually increased NAAG biosynthesis, and the authors
attributed this to the increased availability of radiolabeled
glutamate for NAAG biosynthesis, due to the reduced
incorporation of glutamine and glutamate into proteins. In a
later report, Neale and colleagues used a 30 min pre-incubation
of spinal cord explants with 800 mM ansinomysin, before a
60 min incubation with 3H-glutamine, and found no decrease in
NAAG biosynthesis (Gehl et al., 2004). Again, the radiolabel
incorporation rates were very low (198  66 dpm/mg protein
control versus 219  77 dpm/mg protein with ansiomycin).
These results strongly favor enzymatic synthesis of NAAG
from NAA and glutamate, rather than synthesis as part of a
larger peptide which is then cleaved.
4.1.2. NAA concentration increases NAAG biosynthesis
The evidence to date indicates that NAAG is synthesized by
peptide bond formation between NAA and glutamate, rather
than by acetylation of aspartylglutamate. This suggests that
increased substrate availability in the form of NAA (or
glutamate) might lead to increased NAAG biosynthesis bymass
action, thus implicating Asp-NAT as the first, and possibly
regulatory enzyme in the biosynthetic pathway. Tritiated NAA
injected intracerebroventricularly has been reported to be
incorporated at low levels into NAAG (Sinichkin et al., 1977)
suggesting that NAA acts as a direct precursor for NAAG
synthesis. Gehl and colleagues reported robust NAAG synthesis
in serum-deprived primary rat cortical astrocyte cell culture.
These investigators also showed that cerebellar granule cells,
but not cerebellar astrocytes, could incorporate tritiated
aspartate into NAA, suggesting that if astrocytes can synthesize
NAAG, they must obtain NAA as a precursor from another
cellular source, such as uptake from the extracellular space. In
fact, astrocytes, but not granule cells, were found to take NAA
up from the culture medium. These investigators also showed
that pre-incubation of serum-deprived astrocytes in culture with
unlabeled NAA resulted in significantly increased NAAG
biosynthesis from tritiated glutamate during the course of a
90 min incubation period. These findings are highly suggestive
of the existence of a NAAG synthetase enzyme which ligates
NAA and glutamate, however they differ somewhat from the
results in several other studies which have shown that astrocytes
do not express detectable levels of NAAG (Moffett et al., 1993;
Moffett and Namboodiri, 1995; Passani et al., 1998). It is
possible that certain in vitro conditions, including serum
deprivation, induce astrocytes in culture to produce high levels
of NAAG (Cassidy and Neale, 1993a). The issue of NAAG
synthesis by astrocytes and other glial cells in vivo is an area
requiring further research.
Recently, Arun and coworkers have shown in a continuous
human neuroblastoma cell line (SH-SY5Y) that the addition of
unlabeled NAA to the culture media resulted in a dose-
dependent increase in NAAG synthesis from radiolabeled
precursors (Arun et al., 2006). The average endogenous NAA
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level in SH-SY5Y cells was about 824 ng/mg protein, and these
levels increased to about 1869 ng/mg protein in cells exposed to
10 mM external NAA representing an approximately 2.2-fold
increase in intracellular NAA. This doubling of intracellular
NAA resulted in an approximately 30% increase in NAAG
biosynthesis from radiolabeled glutamine over a 24 h incuba-
tion period, clearly showing a relationship between NAA levels
and NAAG biosynthesis.
5. NAA breakdown and myelin lipid synthesis
Canavan disease affects children throughout theworld, but is
most common in Ashkenazi Jewish and Saudi Arabian families
(Adachi et al., 1973; Matalon et al., 1995). It is not known how
many children are born each year with Canavan disease, and
many cases certainly go undiagnosed. Currently there is no
effective treatment available for restoring proper myelination
and motor function. The pathogenic mechanisms operative in
Canavan disease currently remain a matter of debate, but it has
been proposed that the etiology involves a lack of NAA-derived
acetate, which is required for some portion of myelin lipid
synthesis during postnatal axonal myelination (Hagenfeldt
et al., 1987; Kirmani et al., 2002; Madhavarao et al., 2004,
2005; Mathew et al., 2005; Mehta and Namboodiri, 1995;
Namboodiri et al., 2006a,b). Under this hypothesis, infants born
with Canavan disease are normal at birth because ASPA activity
is not critical until myelin synthesis is dramatically increased
shortly after birth. The maturation of oligodendrocytes and the
myelination of axons in the brain accelerates shortly after birth
(Drobyshevsky et al., 2005). Therefore, the increase in
expression of ASPA that parallels myelination in early
development (D’Adamo et al., 1973; Kirmani et al., 2003)
becomes critical in order to liberate the acetate from NAA for
the synthesis of acetyl CoA, which is necessary for the
synthesis of certain myelin-associated lipids. A number of
studies, including the recent demonstrations of the selective
localization of ASPA in oligodendrocytes in the CNS (Bhakoo
et al., 2001; Kirmani et al., 2002; Klugmann et al., 2003;
Madhavarao et al., 2004), and the increasing NAA concentra-
tions observed by MRS in human fetuses in utero during
development (Girard et al., 2005) are consistent with the
acetate-deficiency hypothesis of Canavan disease.
5.1. Incorporation of acetate moiety of NAA into brain
lipids
It was shown in the 1950s that the concentration of NAA in
the rat brain is low at birth, and reaches adult levels at postnatal
day 20 (Tallan, 1957). This developmental stage in the rat
corresponds to the major period of postnatal myelination in the
brain. In the 1960s, D’Adamo and coworkers showed that the
acetate moiety of NAA was incorporated most efficiently into
brain lipids during CNS development, indicating that it was
likely to be involved in the myelination of axons (D’Adamo
et al., 1968; D’Adamo and Yatsu, 1966). They noted that
reduced but significant incorporation of NAA-derived acetate
into brain lipids occurred in adult rats, suggesting that myelin
turnover in adults involves the breakdown of NAA. In 1987,
Hagenfeldt et al. proposed that the dysmyelination in Canavan
disease was due to failure of N-acetylaspartate to serve as a
carrier of acetyl groups from mitochondria to the cytosol for
lipogenesis (Hagenfeldt et al., 1987). Several years later, Burri
and colleagues showed that the acetate group from NAA was
preferentially incorporated into brain lipids during brain
development as compared with free acetate (Burri et al.,
1991). They also found that NAA-derived acetate incorporation
into brain lipids increased between 8- and 22-day-old rat pups,
whereas incorporation from free acetate during this postnatal
myelination period was constant during development. In the
mid 1990s Mehta and Namboodiri corroborated that radi-
olabeled NAA and acetate were incorporated into acetyl CoA
and brain lipids (Mehta and Namboodiri, 1995). In 2001,
Ledeen and colleagues showed that radiolabeled NAA injected
into the eye was transported down optic nerve axons, and that
the acetate group was incorporated into the ensheathing myelin
(Chakraborty et al., 2001).
5.2. NAA-derived acetate and Canavan disease
Recently, Namboodiri and coworkers demonstrated in the
mouse model of Canavan disease (ASPA / knockout) that
the rate of lipid synthesis in the brain was significantly reduced
at the peak time of myelination (Madhavarao et al., 2005). They
used the 3H2O method for determining the rate of myelination
(Muse et al., 2001) in 17-day-old wild type and ASPA /
mice. Among nonpolar lipids in ASPA / mice, significant
decreases were observed in glycerol 1-fatty acids (decreased by
35%), cholesterol (decreased by 22%), cholesteryl fatty acids
(decreased by 35%), and glycerol trifatty acids (trimyristin,
tripalmitin, trilaurin, and tristearin, decreased by 21%). In
contrast, glycerol 1,2-fatty acids (dimyristin, dipalmitin,
dilaurin, and distearin) were not significantly reduced in the
ASPA / mice. Among polar lipids, phospholipids, and
sulfatides (including phosphatidylinositol, phosphatidyl cho-
line, phosphatidyl glycerol, phosphatidic acid, and cerebroside
sulfate) were decreased by38% in ASPA /mice, whereas
phosphatidyl ethanolamine, galactocerebroside, and hydroxy
fatty acid ceramide, were decreased by 35%. Ledeen and
colleagues have also shown that myelin was decreased
approximately 30% in ASPA / mice, wherein cerebroside
1 was decreased by approximately 65%, and cerebroside 2 was
reduced by approximately 22% (Ledeen et al., 2006). Other
myelin lipids, such as ethanolamine phosphoglycerides, were
only modestly reduced. Many of these types of lipids, including
cerebrosides and sulfatides, are critically important for proper
myelination (Coetzee et al., 1998b; Dupree and Popko, 1999;
Popko, 2000).
Another important observation from studies with ASPA/
mice was that the free acetate levels in their brains were almost
five-fold lower than in wild-type mice at the time of peak
postnatal myelination (Madhavarao et al., 2005). Because the
only defect in these mice is the lack of ASPA activity, the
finding of dramatically lowered brain acetate levels in
developing ASPA / mice demonstrates that NAA is a
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critical source of free acetate in the brain during postnatal
myelination. Exogenously applied acetate has been reported to
be preferentially taken up and utilized by brain astrocytes
(Lebon et al., 2002), but this was only tested between astrocytes
and synaptosomes (Waniewski and Martin, 1998), not between
other cell types from the CNS. Because neurons lack ASPA
activity, it seems likely that NAA is transferred intact from
neurons to oligodendrocytes, where it is then enzymatically
degraded to free acetate and aspartate. In order for free acetate
to participate in lipid synthesis it must first be converted to
acetyl CoA (see Section 5.5 below).
5.3. Other genetic disruptions in myelinogenesis
Leukodystrophies, including Canavan disease, are a class of
genetic disorders that adversely affect axonal myelination or
threaten oligodendrocyte survival, and which in turn result in
either failed development or the destruction of white matter in
the CNS (Maria et al., 2003). Numerous genetic mutations have
been reported to interfere with myelination, either by affecting
myelin lipid synthesis or breakdown, or by detrimentally
affecting myelin-specific proteins (Duncan, 2005). Proper
myelination of neuronal axons requires precise coordination of
protein and lipid synthesis, their integration into oligoden-
drocyte membranes, as well as their subsequent breakdown and
recycling. Genetic mutations that interfere with any point along
the myelin lipid or protein synthetic and degradative pathways
can lead to various severe leukodystrophies (see Fig. 6).
Because axonal loss is often a consequence of dysmyelinating
diseases, MRS has revealed alterations in NAA levels in white
matter in several leukodystrophies.
Pelizaeus-Merzbacher disease is an X-linked recessive
leukodystrophy involving mutations in or duplications of the
gene for proteolipid protein (PLP), a critical myelin-associated
protein in the CNS (Simons et al., 2002). The disease manifests
itself when the gene carries specific mutations, or if multiple
duplications result in three or more copies of the gene (Wolf
et al., 2005). Pathogenesis involves lack of myelination and
Fig. 6. Simplified schematic of NAAmetabolism in neurons and oligodendrocytes, and the relationship to the malate-aspartate mitochondrial shuttle in neurons. The
inner mitochondrial membrane in neurons is shown on the right, and the cytoplasm of oligodendrocytes on the left. Genetic mutations or deletions of the genes for the
proteins designated by an ( ) interrupt the flow of acetate groups from neurons to oligodendrocytes, preventing proper myelin lipid formation. The loss of aspartate-
malate shuttle activity in aralar (/) mice blocks the ability of neurons to supply NAA to oligodendrocytes, thus compromising myelin lipid synthesis. NAAmust be
transported out of neurons and into oligodendrocytes at their areas of contact, sowe can surmise that specific transporters are involved in NAA flux between them. The
fate of NAA derived aspartate in oligodendrocytes is unknown, but it could enter the TCA cycle as oxaloacetate for energy production. Deactivation of ASPA in
oligodendrocytes blocks acetate flux from neurons, in the form of NAA, from getting to the cytosol of oligodendrocytes, where myelin lipid synthesis occurs.
Blocking downstream enzymes in galactolipid synthesis also compromises myelin lipid synthesis, and proper myelination in the CNS. Abbreviations: AAT, aspartate
aminotransferase (EC 2.6.1.1); AcCoA, acetyl coenzymeA; ACS, acetyl CoA synthetase (EC 6.2.1.1); AKG-MT, alpha ketoglutarate-malate transporter; CGT, UDP-
galactose:ceramide galactosyltransferase; MDH, malate dehydrogenase (EC 1.1.1.38).
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relatively late onset axonal degeneration, and the pace of
disease progression depends on the specific mutation involved
(Garbern, 2005). It is thought that mutations in PLP result in
protein misfolding, and buildup in the endoplasmic reticulum.
The resultant endoplasmic reticulum stress in oligodendrocytes
is thought to lead to their death, and subsequent loss of myelin
(Gow et al., 1998). Pelizaeus-Merzbacher disease has also been
associated with alterations in NAA and NAAG levels in brain or
cerebrospinal fluid. Increased levels of NAA in white matter
have been reported by some researchers (Hanefeld et al., 2005;
Takanashi et al., 2002), whereas other studies have reported
decreased levels of NAA in white matter in this dysmyelinating
disease (Pizzini et al., 2003). Increased NAAG in the
cerebrospinal fluid has also been reported in patients with
Pelizaeus-Merzbacher disease (Burlina et al., 2006a).
An extremely rare leukodystrophy is associated with very
high levels of NAAG in the cerebrospinal fluid (Wolf et al.,
2004). The disorder has been reported in two unrelated girls and
is characterized by severe hypomyelination, absence of
psychomotor development, and a near complete lack of
myelination in cerebral MRI scans. In another remarkable
case, a child with reduced myelination, psychomotor retarda-
tion, secondary microcephaly and seizures was reported to have
brain NAA levels too low to detect by MRS, possibly due to a
genetic mutation in the gene for the NAA synthetic enzyme
Asp-NAT (Boltshauser et al., 2004; Burlina et al., 2006b). In
this single known case of hypoacetylaspartia, NAA and NAAG
were also undetectable in the patient’s cerebrospinal fluid by
capillary electrophoresis. Interestingly, urinary levels of NAA
and NAAG were found to be near normal in this patient,
suggesting low levels of NAA and NAAG synthesis in the brain.
The specific biochemical or metabolic links between altered
NAA and NAAG levels and dysmyelination in various
leukodystrophies remain to be fully elucidated, but all of these
findings point to NAA and NAAG as having roles in axonal
physiology, axon-glial interactions, and the production and
maintenance of the myelin sheath.
A recent study has shown that mice lacking the gene for
aralar1, a mitochondrial aspartate-glutamate transporter,
demonstrated pathologies similar to ASPA / mice (Jalil
et al., 2005), including dysmyelination (Fig. 6). The authors
relate the dysmyelination observed in these mice to a lack of
synthesis of aspartate, and resultant drastic reductions in NAA
levels in the brain. The lack of NAA-derived acetate then leads
to reduced myelin lipid synthesis and leukodystrophy, as is the
case with ASPA / mice. An important observation
concerning the dysmyelination in aralar1 deficient mice was
that only select lipids were significantly reduced in the brain,
including galactocerebrosides. These data provide additional
evidence for NAA as being a major source of free acetate and
acetyl CoA for lipid synthesis in the brain during development,
and that NAA-derived acetate is critical for proper CNS
myelination.
Other possible genetically based disruption points in
myelinogenesis could include Asp-NAT, the alpha ketogluta-
rate-malate transporter, any mitochondrial or plasma membrane
NAA transporters that are necessary to transfer NAA from
neuronalmitochondria to the cytoplasmofoligodendrocytes, and
finally, acetyl CoA synthetase in oligodendrocytes (see Fig. 6). If
redundant metabolic and transport pathways do not exist,
mutations in genes for all of these proteins could theoretically
lead to various leukodystrophies (Boltshauser et al., 2004).
CNS myelination is a demanding biological process that
requires the precise control of gene expression, protein
translation, protein folding, complex lipid synthesis, and the
proper assembly of these components into the intricate
architecture of the myelin sheath. Further, the maintenance
of myelin requires a continuous and dynamic process of myelin
component catabolism and recycling (Ando et al., 2003). Errors
in any of these myelination-related functions can lead to
dysmyelination and axonal degeneration. ASPA deficiency
represents just one of the many vulnerabilities in the cellular
apparatus required for myelin production via which leukody-
strophies manifest white matter pathology. Further, perturba-
tions in NAA and NAAG physiology appear to have important
connections to myelination, providing fascinating avenues for
further research into the production and maintenance of the
myelin sheath.
5.4. Central versus peripheral myelination
The processes of central and peripheral axonal myelination
are accomplished by partially distinct mechanisms (Dupree
et al., 1998; Fujita et al., 1998). The myelinating cells of the
CNS and PNS are distinct, with each oligodendrocyte
myelinating multiple axonal internodes in the CNS, but
Schwann cells providing myelination for a single peripheral
axonal internode. Many of the proteins expressed by
oligodendrocytes and Schwann cells are distinct. For example,
the major myelin-associated proteins in the CNS are PLP, its
alternative splice variant DM20 and myelin basic protein
(Garbern, 2005), whereas the predominant myelin-associated
proteins in the PNS are protein zero (PO), peripheral myelin
protein 22 kDa (PMP22) and myelin basic protein (Brown and
Lemke, 1997; Jiang et al., 2000).
Mutations that affect myelination can have distinct effects
on myelin formation in the CNS and PNS. For example,
galactolipid-deficient mice have a CNS myelination disorder,
but myelination in the PNS is far less affected in these animals
(Coetzee et al., 1998a). Specifically, mice deficient in UDP-
galactose:ceramide galactosyltransferase, a critical enzyme in
the biosynthetic pathway to galactocerebroside and sulfatide,
have reduced myelination, and exhibit myelin-related abnorm-
alities in the CNS (see Fig. 6). However, myelination in the PNS
was found to be normal, except for a transient increase in
myelin sheath-axonal detachments at postnatal day 10. It has
also been shown that the gene for ASPA, which is expressed
strongly in oligodendrocytes in the CNS, is not expressed
significantly in the peripheral nervous system (Kirmani et al.,
2003), suggesting a specific role for the NAA degrading
enzyme in CNS myelination, but not in peripheral myelination
mediated by Schwann cells. It is interesting in this regard that
aralar1 / mice showed reduced levels of galactocerebro-
cides in the CNS, but not in the PNS, providing further support
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for a role of NAA-derived acetate in synthesis of specific lipids
in the brain, but not in peripheral nerves (Jalil et al., 2005).
Further, connexin Cx32 is a gap junction protein expressed in
both oligodendrocytes and Schwann cells, and Cx32 mutations
are associated with X-linked Charcot–Marie–Tooth disease, a
peripheral demyelinating disease in which central myelination
is unaffected (Menichella et al., 2003). All of these findings
point to distinct mechanisms of myelin formation in the central
and peripheral nervous systems.
5.5. Unique aspects of CNS lipid metabolism
In the 1960s D’Adamo and colleagues showed that the
incorporation of the acetate moiety of NAA into fatty acids in
the brain during myelination was three times greater than from
free acetate (D’Adamo et al., 1968; D’Adamo and Yatsu, 1966).
They made note of the growing evidence suggesting that the
control of fatty acid and sterol synthesis in the CNS is different
from those in other tissues. Indeed, the evidence has since
grown substantially demonstrating that brain lipid synthesis,
like brain energy metabolism, is mechanistically distinct from
lipid synthesis in many peripheral tissues. Both energy
metabolism and lipid synthesis require a continuing supply
of acetyl CoA, as does the synthesis of NAA (Fig. 7). However,
the generation of acetyl CoA is a complex, and poorly
understood aspect of lipid synthesis (Nikolau et al., 2000). In
many peripheral tissues, cells produce most or all of the acetyl
CoA required for fatty acid synthesis by the action of the
enzyme ATP citrate lyase (EC 2.3.3.8) (Goldberg and
Brunengraber, 1980; Jones and Ashton, 1976). The primary
source of carbon units for lipid synthesis through this lipogenic
pathway is glucose (Bauer et al., 2005), and free acetate is not
involved at any step. In the cytosol, ATP-citrate lyase catalyses
the reaction of citrate and CoA to produce oxaloacetate and
acetyl CoA, and the acetyl CoA produced can be used in turn
for the synthesis of fatty acids and cholesterol.
It seems likely that lipid metabolism differs in neurons and
glia. For example, studies on themetabolismofN-acetylcarnitine
in the brain have shown that glucose and N-acetylcarnitine have
different lipogenic fates suggesting the existence of distinct
lipogenic acetyl CoA pools in different cell types, or different
subcellular compartments (Ricciolini et al., 1998). Evidence
from studies of lipogenesis in intestinal colonocytes also points
to cell-specific mechanisms of lipid synthesis. Colonocytes are
rapidly dividing cells which synthesize the bulk of their own
cholesterol and fatty acids from substrates such as acetate and
butyrate derived from bacterial metabolism in the gut. When
incubated with [14C]-labeled substrates including glucose,
glutamine, proprionate, hydroxybutyrate, butyrate, and acetate,
it was found that acetate provided more carbon to lipids than the
other substrates, indicating that TCA-generated acetyl CoAwas
not significantly involved in de novo lipid synthesis in
colonocytes (Zambell et al., 2003). Further, hydroxycitrate did
not inhibit acetate incorporation into lipids in these cells,
suggesting that the citrate lyase reaction was not critical for lipid
synthesis. So unlike liver cells, colonocytes do not use TCA-
derived acetyl CoA as the primary carbon source for lipid
synthesis. Oligodendrocytes in the brain may also make use of a
similar alternate pathway of acetyl CoA production involving
free acetate. Indeed, a citrate lyase independent pathway of
acetate incorporation into sterols has been reported in calf brain
oligodendrocytes in culture (Pleasure et al., 1979).
Fig. 7. Three major fates for acetyl CoA produced in neurons. Acetyl CoA can
be used in neurons for lipid synthesis via the ATP citrate lyase pathway, or
energy production via the TCA cycle. When local energy and lipid synthesis
demands have been met, a third route of acetyl CoA utilization present in
neurons is the Asp-NAT mediated synthesis of NAA using aspartate as co-
substrate, followed by export to oligodendrocytes for further metabolism.
Pathologies that impair neuronal energetics would be expected to reduce
NAA production as acetyl CoA is diverted to energy production and membrane
lipid synthesis.
Fig. 8. Two different methods of acetyl CoA synthesis leading to fatty acid
synthesis. The ASPA/NAA system may only be critical for acetyl CoA (AcCoA)
synthesis in certain cells types, such as oligodendrocytes (left), whereas the ATP
citrate lyase system is present in most cell types (right). In cells other than
oligodendrocytes, citrate provides the substrate for acetyl CoA synthesis. In
oligodendrocytes, the ATP citrate lyase system is active, but in addition, NAA is a
major substrate for the increased acetyl CoA synthesis required during postnatal
myelination. In order to participate in lipid synthesis, the acetate derived from
NAA in the cytoplasm of oligodendrocytes must be converted to acetyl CoA,
possibly by the enzyme acetyl CoA synthetase-1. Abbreviations: AcCoA, acetyl
coenzymeA;ACL, ATP citrate lyase (EC 2.3.3.8); ACS, acetyl CoA synthetase-1
(EC 6.2.1.1); ASPA, aspartoacylase (EC 3.5.1.15); CoA-SH, coenzyme A.
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In oligodendrocytes, it now appears that ASPA and NAA are
required as an adjunct method of producing acetyl CoA for fatty
acid synthesis, via the sequential actions of ASPA and acetyl
CoA synthetase-1 (ACS1; EC 6.2.1.1), the other major enzyme
involved in acetyl CoA synthesis (Fig. 8). In preliminary
experiments with recently generated antibodies to ACS1, we
have observed expression of this enzyme in a sub-population of
oligodendrocytes in the adult rat brain, which is consistent with
a role in myelin lipid formation (unpublished observations).
Radiolabeled carbon infusion and feeding experiments show
much more rapid turnover of the acetate carbon in NAA than
the aspartate moiety (Karelson et al., 2003), suggesting that the
acetate from NAA is highly active in brain metabolism,
particularly lipid synthesis during myelination. ATP citrate
lyase is strongly expressed in the developing brain, and ATP
citrate lyase-deficient mice die early in development, high-
lighting the essential nature of this reaction in many cell types,
and the fact that ACS-1 can not compensate for the loss of the
citrate lyase pathway (Beigneux et al., 2004). It appears likely
that the brain uses both of these acetyl CoA synthesizing
pathways together to meet the strong demand for lipid synthesis
in the brain during postnatal myelination. The ASPA–ACS1
pathway in this view is a parallel pathway for acetyl CoA
production and lipogenesis. Based upon observations that
certain classes of lipids are deficient in the brains of ASPA/
mice, while others are unaffected, it seems likely that the
ASPA–ACS1 pathway is only critical for the formation of
certain classes of lipids, in particular, steroids, cerebrosides and
sulfatides. This raises the possibility that ACS1 knockout mice
would not die before birth, because the ATP citrate lyase
pathway in the brain would be sufficient for most or all prenatal
lipid synthesis. However, much like ASPA / mice, ACS1
knockout mice may display postnatal symptoms similar to
Canavan disease due to reduced acetyl CoA availability for
myelin-related lipogenesis. It is noteworthy that aralar /
mice, which lack aspartate-malate shuttle activity, show large
reductions in galactocerebrocide levels in the CNS, while many
other lipid classes appear unaffected (Jalil et al., 2005).
6. NAA in neuronal energy metabolism
The earliest indication that NAA could be involved in energy
metabolism was the second report by Harris Tallan in which he
showed that NAA was present at high concentrations in the
brains of birds and mammals, and that the distribution pattern
closely paralleled the distribution of ‘‘respiratory activity’’
(Tallan, 1957). A subsequent report by Buniatian and
coworkers in 1965 also indicated that NAA might be involved
in brain energy metabolism (Buniatian et al., 1965). Using rat
brain cortical slices these investigators showed that glucose
addition caused increased NAA levels and increased release of
NAA into the medium, and that the absence of added glucose
led to reduced NAA levels in the brain slices. In 1972 Nadler
and Cooper injected radiolabeled NAA into rat brains and
found two distinct metabolic compartments or pools which they
associated with what appeared to be two distinct citric acid
cycles in the brain, termed the ‘‘synthetic cycle’’ and the
‘‘energy cycle’’ (Nadler and Cooper, 1972a). Uptake and
metabolism of NAA was rapid in the smaller synthetic cycle,
and slower in the much larger energy cycle. It is likely that the
distinct cycles were present in different cell types in the CNS, as
discussed below.
6.1. ATP synthesis and NAA synthesis are coupled
In 1979, Patel and Clark provided the first direct evidence
showing a relationship between NAA synthesis and energy
metabolism (Patel and Clark, 1979). They found that brain-
derived mitochondrial preparations were distinct from those
derived from other tissues in that they synthesized large
amounts of NAA. Using isolated rat brain mitochondria, Patel
and Clark demonstrated the synthesis and efflux of NAA from
mitochondria incubated in the presence of glutamate and
malate, plus either pyruvate or 3-hydroxybutyrate. The
synthesis of NAAwas stimulated by ADP (mitochondrial state
3), used glutamate as a transamination source for aspartate, and
either pyruvate or 3-hydroxybutyrate as a source of acetyl CoA.
An important finding of this study was that there was a
reciprocal relationship between aspartate efflux and NAA
efflux when rat brain mitochondria oxidized glutamate
(10 mM) and malate (2.5 mM) in the presence of various
concentrations of pyruvate. Without pyruvate as a source of
acetyl CoA, no NAA efflux was detected. Increasing pyruvate
concentrations caused a decrease in aspartate efflux, and an
increase in NAA efflux. However, NAA efflux did not replace
aspartate efflux completely even at the highest concentration of
pyruvate. Instead, the decrease in aspartate efflux reached a
plateau at about 60% of the efflux levels observed in the
absence of pyruvate. Similarly, NAA efflux also reached a
maximum at about the same concentrations of pyruvate. Given
that their preparations contained both neuronal and nonneur-
onal mitochondria, the above observation could reflect the
inability of nonneuronal mitochondria to synthesize NAA.
In a subsequent study with rat brain mitochondria, Clarke
and associates showed that NAA synthesis is decreased when
oxygen consumption and ATP production are decreased using
irreversible inhibitors of complexes III, IV, and V of the
mitochondrial respiratory chain (Bates et al., 1996). This study
showed a biochemical coupling between NAA synthesis and
energy production in brain mitochondria. This coupling
relationship has been subsequently substantiated by additional
reports noting decreases in NAA in a number of conditions of
impaired energy metabolism in the brain, which are described
below. For an overview of the data supporting a bioenergetic
role for NAA in neurons, see (Clark, 1998).
6.2. Impairments in energy metabolism decrease NAA
levels in brain
There are a number of experimental paradigms that have
demonstrated decreases in NAA levels when brain energy
metabolism is impaired by different mechanisms. Studies on
traumatic brain injury have consistently shown decreased NAA
levels in the brain using different model systems, and the
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decreases in NAA and ATP were temporally correlated,
suggesting that the NAA reductions are related to energetic
impairment (Gasparovic et al., 2001; Signoretti et al., 2001,
2004; Tavazzi et al., 2005; Vagnozzi et al., 2005). The
reductions in NAA and ATP were positively correlated with the
severity of the brain injury. In one study, cyclosporine showed
neuroprotective properties by ameliorating mitochondrial
damage, and helped to minimize the reductions in ATP and
NAA (Signoretti et al., 2004). Based on research connecting
NAA synthesis to ATP levels, measurement of NAA by
magnetic resonance spectroscopy has been proposed as a non-
invasive tool to monitor the recovery of brain energy
metabolism following brain injury in a clinical setting.
Another experimental paradigm involves rat and primate
models of progressive striatal neurodegeneration induced by
the mitochondrial toxin 3-nitropropionic acid (3-NP). In rats
treated with 3NP, NAA decrease was observed selectively in the
striatum before any cell loss, but was associated with motor
symptoms (Demougeot et al., 2001). Also, a similar selective
and early striatal decrease in NAAwas observed in 3-NP treated
primates (Dautry et al., 2000). The early decrease in striatal
NAAwas partially reversed after 3 weeks of 3-NP withdrawal.
These results suggest that NAA depletion reflects a reversible
state of neuronal dysfunction and raise the possibility that
quantitation of NAA by MRS might be a valuable tool to assess
neuronal dysfunction and the effects of potential neuroprotec-
tive therapies. Interestingly, in another study, the NAA decrease
in response to 3-NP was associated with an increase in acetate
(Lee et al., 2000). However, the origin of this increased acetate
remains unclear.
The mouse model for Huntington’s disease is another
experimental paradigm wherein decreases in NAA levels are
well documented. The drop in brain NAA levels commenced at
about 6 weeks of age and coincided with the onset of symptoms
(Jenkins et al., 2000). These decreases in NAA occurred in the
absence of any neuronal cell death. Also, dietary creatine
supplementation significantly improved survival, slowed
development of brain atrophy and delayed decreases in NAA
(Andreassen et al., 2001; Ferrante et al., 2000). These results
also indicate that the levels of NAA in the brain reflect the
health of neurons and are a reliable marker for monitoring
neuronal energy impairment and dysfunction.
The overall weight of the evidence favors a link between
NAA synthesis in neuronal mitochondria and energy metabo-
lism, but studies have so far failed to make a direct connection
between the synthesis of NAA and that of ATP. It is quite
possible that the linkage between the syntheses of these two
molecules is more indirect, for example, NAA synthesis can be
considered an energy requiring process in the sense that it is
dependent on the energy consuming synthesis of acetyl CoA.
6.3. A model of NAA synthesis linked to mitochondrial
energetics in neurons
Studies of brain metabolism suffer from the fact that
different cell types in the brain have mitochondria with
different biochemical properties and pathways. Neurons and
glia take up and metabolize different key metabolites, and
express different complements of metabolic enzymes. The
predominant astroglial localization of glutamine synthase
permits the metabolism of glutamate to glutamine in astrocytes
(Martinez-Hernandez et al., 1977; Norenberg and Martinez-
Hernandez, 1979; Schousboe et al., 1997), which can then be
excreted to the circulation, or recycled to neurons for
conversion back to glutamate (Cooper, 2001). As discussed
in Section 2.1, neuronal mitochondria express Asp-NAT, a
unique enzyme which synthesizes NAA (Benuck and
D’Adamo, 1968; Goldstein, 1969; Madhavarao et al., 2003;
Truckenmiller et al., 1985). It had been proposed in the 1970s
that NAA synthesis in neuronal mitochondria might be a
mechanism for transporting carbon from the mitochondrial
matrix to the cytoplasm (Miller et al., 1996; Patel and Clark,
1979), much as citrate does in other cell types (Clark, 1998).
However, this proposal was made before the discovery that the
NAA degrading enzyme ASPAwas not present in neurons, but
instead was expressed predominantly in oligodendrocytes
(Baslow et al., 1999; Kirmani et al., 2002; Madhavarao et al.,
2004). The possibility that one function of NAA is to move
acetate carbon units from neuronal mitochondria to the
cytoplasm of oligodendrocytes was discussed above in Section
5.1.
Glucose is thought to be the primary energy source in brain,
and there is controversy over the importance of other potential
energy substrates, such as lactate (Aubert et al., 2005). Some
studies have reported that the brain can use lactate for energy
production (Tabernero et al., 1996; Tyson et al., 2003), but these
findings have been disputed by other investigators (Chih and
Roberts, 2003; Fillenz, 2005). Amino acids have also been
proposed as possible sources of energy in brain metabolism.
Removal of glucose greatly accelerates glutamate transamina-
tion to aspartate in brain synaptosomes, suggesting that
glutamate could be an energy source in the brain under some
circumstances (Erecinska et al., 1988). The enzyme in
mitochondria that accomplishes the task of glutamate
transamination is aspartate aminotransferase (EC 2.6.1.1,
AAT; also known as aspartate transaminase), which consumes
oxaloacetate and glutamate to produce aspartate and alpha
ketoglutarate (see Figs. 6 and 8). Because alpha ketoglutarate
can directly enter the TCA cycle for energy production, it is
possible that glutamate could be used to meet the extra demand
for ATP in neurons by oxidation of glutamate starting with the
aspartate aminotransferase reaction.
The potentially important role of aspartate aminotransferase
in facilitating respiration on glutamate in neuronal mitochon-
dria was recognized by earlier investigators, and the name ‘mini
citric acid cycle’ was coined to emphasize its role in neuronal
energetics (Erecinska et al., 1988; Yudkoff et al., 1994). This
truncated TCA cycle in neurons bypasses citrate and isocitrate
formation as shown in Fig. 9. Based on data obtained using
radiolabeled aspartate and glutamine in rat brain synaptosomal
preparations, Yudkoff, Erecinska and colleagues proposed that
in the brain, amino acids could provide an alternative source of
energy to help maintain ATP levels (Yudkoff et al., 1994). They
made several important observations, including that in brain
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synaptosomes, the fastest reaction that supplies metabolites to
the TCA cycle is aspartate aminotransferase, and the slowest
step is from oxaloacetate to citrate. They also noted that
bypassing the citrate synthase reaction, which consumes acetyl
CoA and oxaloacetate to produce citrate, spares the mitochon-
drial pool of acetyl CoA, which then could be used for other
reactions, including the synthesis of NAA (see Fig. 9).
The truncated TCA cycle in neurons starts from glutamine,
and proceeds through glutamate to alpha ketoglutarate without
the action of glutamate dehydrogenase (EC 1.4.1.3), which
would involve the production of ammonia. Glutamate
dehydrogenase is present in neurons and glia (McKenna
et al., 2000), and catalyzes the deamination of glutamate to
alpha-ketoglutarate and ammonia using either NAD or NADP
as cofactors (Mastorodemos et al., 2005). It is possible that
neuronal mitochondria preferentially use the aspartate amino-
transferase reaction instead of the glutamate dehydrogenase
reaction to generate the key metabolite alpha ketoglutarate in
order to avoid the problem of ammonia toxicity (Madhavarao
et al., 2003, 2005; Madhavarao and Namboodiri, 2006). This
metabolic distinction between neurons and somatic cells such
as hepatocytes may be due in part to the absence of an effective
urea cycle system in the brain for nitrogen removal (see Section
7 below).
In addition to acetyl CoA, NAA synthesis requires a
continuous supply of aspartate in neuronal mitochondria. The
aspartate-malate shuttle is a critical component of the inner
membrane of neuronal mitochondria (Yudkoff et al., 1994),
which moves reducing equivalents from the cytosol into
mitochondria in the form of malate (Ramos et al., 2003).
Intramitochondrial malate is then rapidly converted through
oxaloacetate to aspartate via the aspartate aminotransferase
reaction (Yudkoff et al., 1994). The aspartate-malate shuttle is
essential for this process, and it involves several proteins and
enzymes in mitochondria and the neuronal cytoplasm (see
Fig. 6). Aralar1 is a key glutamate-aspartate transporter involved
in the aspartate-malate shuttle in the mitochondria of certain
tissues, notably excitable tissues including skeletal muscle, heart
and brain (Begum et al., 2002). Aralar1 moves aspartate out of
mitochondria, and glutamate into mitochondria, and works in
conjunction with the enzyme aspartate aminotransferase, which
is another integral part of the malate-aspartate shuttle. Results
with aralar1/mice also provide support for the bioenergetic
role for NAA linked to the aspartate-malate shuttle (Jalil et al.,
2005). Aralar1 is the only mitochondrial aspartate-glutamate
carrier in the brain, and aralar1 / mice lack malate-aspartate
shuttle activity, have dramatically reduced brain NAA and
aspartate levels, and show reduced neuronal respiration on
glutamate plus malate (Jalil et al., 2005). It is possible that the
acetylation of aspartate by Asp-NAT in neuronal mitochondria
could combine with the action of aralar1 to remove product
inhibition of the aspartate aminotransferase reaction. This would
facilitate the conversion of glutamate to alpha ketoglutarate that
can then enter theTCAcycle for energy production (Madhavarao
et al., 2003, 2005; Madhavarao and Namboodiri, 2006).
There have been a number of reports which do not support a
bioenergetic role for NAA synthesis in the brain. Magnetic
resonance spectroscopy studies on the indices of mitochondrial
energetics in healthy individuals did not find a positive
correlation between NAA levels and ATP (Pan and Takahashi,
2005). The lack of correlation between brain ATP and NAA
levels was based entirely on in vivo MRS data. In addition, the
determined concentration levels of free ADP and ATP varied by
a factor of 1000. In terms of concentration however, NAA levels
were comparable to those of ATP rather than ADP. It should
also be noted that MRS techniques average ATP, ADP, and
NAA levels over a relatively large volume of tissue, which
would contain all cell types present in the brain, thus averaging
metabolite concentrations which may have large intercellular
gradients. NAA synthesis in the brain has been shown to be
coupled to glycogen and glucose metabolism (Choi and
Gruetter, 2003; Moreno et al., 2001), but did not appear to be
substantially involved in brain energy stores in the resting brain
(Choi and Gruetter, 2004). Finally, the work of Lu and
colleagues suggests that microsomal synthesis of NAA may be
quantitatively more robust than mitochondrial synthesis (Lu
et al., 2004), which would diminish any role for NAA in
neuronal energy production. Much additional work will be
required to determine the relative contributions of mitochondria
and other compartments such as endoplasmic reticulum to
NAA synthesis in neurons.
Fig. 9. Schematic of the proposed ‘‘mini-TCA cycle’’ in neuronal mitochondria
(Yudkoff et al., 1994), and the connection to NAA synthesis. Gray lines indicate
the neuron-specific portion of the truncated TCA cycle, and the link to NAA
synthesis, whereas dashed lines indicate the part of the TCA cycle that can be
bypassed when oxidizing glutamate. As glutamate is converted to alpha
ketoglutarate, the truncated TCA cycle produces excess aspartate, and the
aspartate can be removed by acetylation through Asp-NAT (Madhavarao et al.,
2005; Madhavarao and Namboodiri, 2006). The figure emphasizes the central
role of aspartate aminotransferase (AAT) in the ability of neuronal mitochondria
to bypass the slower citrate synthase reaction, and to oxidize glutamate through
the truncated portion of the TCA cycle. There is no net cost in acetyl CoA
utilization during the synthesis of NAA via Asp-NAT, because citrate produc-
tion is circumvented. Reduced citrate production in neurons may reduce
substrate availability for local lipid synthesis via the citrate lyase reaction
(Fig. 8), but extra NAA is generated which can then be exported and used for
increased galactocerebroside and steroid synthesis in oligodendrocytes.
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6.4. Fate of NAA in oligodendrocytes after postnatal
myelination
A central question regarding any model of NAAmetabolism
concerns the role of the NAA-derived aspartate that is formed in
oligodendrocytes as a result of ASPA-mediated catalysis. A
study from Yudkoff and coworkers provides some clues
concerning this important question (Miller et al., 1996). They
found that intracranial injection of N-([2H3] acetyl)-L-[
15N]-
aspartate ([2H3,
15N]NAA) led to its rapid decline which was
associated with a rapid and quantitative appearance of [15N]
glutamate. This finding indicated rapid transamination of the
[15N] aspartate that was derived from the ASPA-mediated
hydrolysis of [2H3,
15N]NAA. Also, [15N]NAA was not
detectable, indicating that [15N] aspartate was not reutilized
for NAA synthesis. These results are consistent with the
deacetylation of NAA taking place almost exclusively in
oligodendrocytes, and the resulting aspartate being utilized for
energy production in the citric acid cycle after conversion to
oxaloacetate. Concerning the fate of NAA derived acetate in
oligodendrocytes after postnatal myelination is complete, it
should be noted that acetyl CoA is involved in numerous critical
cellular reactions, and it can be degraded to CO2 through the
TCA cycle for the derivatization of energy (Bluml et al., 2002).
Therefore, NAA can supply both acetate and oxaloacetate to the
TCA cycle for energy production (Nadler and Cooper, 1972a),
at least in oligodendrocytes where ASPA is present. Glial cells
preferentially utilize acetate for energy production through the
TCA cycle, as opposed to neurons (Bluml et al., 2002; Hassel
et al., 1995; Muir et al., 1986) suggesting that oligodendrocytes
could make substantial use of NAA-derived acetate for energy
production when myelination is complete. It has also been
proposed that NAA could act as a reservoir of glutamate in the
brain, wherein NAA is converted to aspartate in oligoden-
drocytes, which could then be converted to glutamate through
the TCA cycle with favorable energetics (Clark et al., 2006).
7. Integrating various NAA functions in the CNS
Recently, Madhavarao and coworkers proposed a model
whereby NAA has two primary roles in the nervous system;
facilitation of energy metabolism in neuronal mitochondria,
and a source of acetate for fatty acid and steroid synthesis in
oligodendrocytes. In this model, Asp-NAT facilitates removal
of excess aspartate from the matrix of neuronal mitochondria
via acetylation, thus favoring alpha ketoglutarate formation
from glutamate, and energy production via the citric acid cycle.
Anaplerosis and cataplerosis are the complimentary metabolic
processes which replenish TCA cycle intermediates, and
remove excess intermediates, respectively (Brunengraber and
Roe, 2006). Principle anaplerotic molecules feeding into the
TCA cycle include pyruvate, glutamate, and precursors of
propionyl-CoA. Two important cataplerotic enzymes that help
remove excess TCA intermediates are aspartate aminotransfer-
ase and citrate lyase (Owen et al., 2002). We propose that Asp-
NAT also plays a cataplerotic role in neuronal mitochondria.
NAA synthesis is associated with preventing product inhibition
of aspartate aminotransferase by using the Asp-NAT reaction to
remove excess aspartate from neuronal mitochondria. The
malate-aspartate shuttle in neuronal mitochondria is required
for aspartate synthesis by providing the precursor malate, and
as such, shuttle activity is required for NAA synthesis in
neuronal mitochondria. Converting the product aspartate into
NAA helps to guide the aspartate aminotransferase reaction
toward alpha ketoglutarate, thus facilitating energy production
in neurons. Using this reaction would also spare acetyl CoA
from the citrate synthetase reaction, so that it could participate
in NAA synthesis instead.
In its lipogenic role, Asp-NAT activity works in conjunction
with a putative mitochondrial NAA transporter to move acetate
groups from the matrix of neuronal mitochondria to the
cytoplasm in the form of NAA. Neuronal NAA must then be
transferred to oligodendrocytes at their point of contact; the
inner plasma membrane of the myelin sheath. It seems likely
that specific dicarboxylate transport proteins or exchangers in
both neurons and oligodendrocytes are involved in this process
(Fujita et al., 2005). After axonal-glial transfer of NAA to
oligodendrocytes, it provides acetate units for fatty acid and
steroid synthesis in the cytosol via the actions of ASPA and
cytoplasmic acetyl CoA synthetase (ACS1). The activity of
ACS1 in the brain has been poorly characterized (Luong et al.,
2000), but it may turn out to be another lipogenic enzyme
present in oligodendrocytes that works in conjunction with
ASPA. The proposed model stresses the trophic support
between neurons and oligodendrocytes, where neurons supply
oligodendrocytes with NAA-derived acetyl groups for fatty
acid synthesis, and in turn, oligodendrocytes synthesize the
critical myelin lipids, including sulfatide, galactocerebroside
and cholesterol, which are essential for myelination and proper
neuronal function (Fig. 6). When lipid synthesis requirements
have been met in oligodendrocytes, acetyl CoA and aspartate
can be utilized for other functions, including protein synthesis
and energy production.
7.1. Four cell-type model for NAA synthesis, utilization,
breakdown and excretion
In order to place NAA metabolism in the CNS in a broader
context, it is necessary to discuss intercellular trafficking of the
relevant metabolites (Fig. 10). The blood stream acts as both the
source and sink for all brain metabolites, including glucose,
amino acids and waste products. Endothelia and astrocytes
provide a two-stage selective barrier to metabolite diffusion
into and out of the brain in the form of the blood–brain barrier.
Glucose is the brain’s primary energy source by providing the
starting substrate for pyruvate production in neuronal
cytoplasm, and utilization in mitochondria. Pyruvate is
converted to acetyl CoA, which can enter the TCA cycle for
oxidation. Additionally, acetyl CoA and aspartate can act as
substrates for the synthesis of NAA, mediated by the enzyme
Asp-NAT. Some portion of NAA in select neuronal populations
is combined with glutamate to form NAAG, probably by a
dipeptide synthetase. The bulk of the brain’s complement of
NAA remains intraneuronal, and turns over relatively slowly.
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Some NAA is released in a controlled fashion from neurons as
an osmolyte or nitrogen carrier (see Section 7.1.1 below), or
effluxes to extracellular space along its concentration gradient,
where it is most likely taken up by astrocytes. NAAG released
from neurons upon depolarization is either taken up by neurons,
or is broken down to NAA and glutamate on the surface of
astrocytes, which then take up both compounds. Some NAA is
transported from neuronal axons to oligodendrocytes at their
point of contact, and it is then broken down to acetate and
aspartate within the oligodendrocytes. Acetate can be
incorporated into acetyl CoA and then converted to lipids, or
fully oxidized in the TCA cycle for energy. Aspartate can be
used for protein synthesis, or can be converted to oxaloacetate
for subsequent energy production. Ammonia produced in
neurons by the enzyme glutaminase escapes to the extracellular
space, and then into astrocytes where it participates in the
glutamine synthetase reaction to produce glutamine. Glutamine
can be passed back to neurons for conversion to glutamate and
ammonia, or if the brain nitrogen load is high, the glutamine can
be excreted from astrocytes to the circulation.
Fig. 10. Hypothetical, simplified four-cell model of NAA synthesis and metabolism in the brain. NAA is synthesized in neuronal mitochondria (see Fig. 5), and can
then either be transported to oligodendrocytes for fatty acid synthesis and energy production, or can be used for the synthesis of NAAG in neurons. NAAG is released
from neuronal synapses along with other transmitters, such as glutamate, and the extracellular NAAG is hydrolyzed by GCPII on astrocytes, which then take up the
breakdown products (blue lines). Glutamate and ammonia in astrocytes are converted to glutamine by glutamine synthase (GS), and the glutamine can be excreted to
the circulation as a nitrogen removal system, or it can be transported back to neurons for reuse. When the brain nitrogen load is high, NAA excretion might act as a
secondary nitrogen removal system, wherein NAA could hypothetically be released by neurons to the extracellular space, taken up by astrocytes, and then excreted to
the circulation (red lines). Glutamate and glutamine cycling between neurons and astrocytes involves the production and detoxification of ammonia. Abbreviations:
ASP, aspartate; ASPA, aspartoacylase; GCPII, glutamate carboxypeptidase II; GLN, glutamine; GLU, glutamate; GS, glutamine synthetase; NAA,N-acetylaspartate;
NAAG, N-acetylaspartylglutamate; NH3, ammonia.
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When glutamine and other amino acids are limiting in
neurons, there would be less flux through the aspartate
aminotransferase pathway of the truncated TCA cycle, and
neuronal respiration would occur primarily through pyruvate
conversion to acetyl CoA, and the synthesis of citrate from
oxaloacetate and acetyl CoA. But when the nitrogen load in
brain is increased, and excess glutamine is present, flux through
aspartate aminotransferase would be accelerated, and both
alpha ketoglutarate and aspartate would be formed. The alpha
ketoglutarate could be oxidized through the TCA cycle, and the
excess aspartate could be acetylated to NAA. A possible fate of
NAA that has not been explored is that it could function as a
secondary mechanism for nitrogen removal from the brain.
7.1.1. Possible role for NAA in CNS nitrogen balance
Nitrogen balance involves the strict regulation of amino acid
uptake, protein synthesis and degradation, amino acid excretion
and amino acid oxidation. In the brain, as in other organs, the
carbon skeletons of amino acids are oxidized for energy or
stored as glycogen, but the excess amino nitrogen must be
excreted. Ammonia metabolism in the brain is intimately
associated with nitrogen recycling and removal. The primary
route of ammonia metabolism and detoxification in brain is
accomplished by the enzyme glutamine synthase in astrocytes
(Cooper, 2001). This enzyme system not only efficiently
removes ammonia from the blood as it enters the brain, but also
detoxifies ammonia released from neurons. Neurons release
glutamate and ammonia, and astrocytes take up both
metabolites and produce glutamine through the glutamine
synthase reaction, thus preventing ammonia toxicity. Excess
glutamine in astrocytes is excreted to the bloodstream as
required by the brain’s nitrogen load.
The brain lacks the urea cycle enzymes carbamoyl-
phosphate synthase I and ornithine transcarbamylase, and
therefore is unable to remove nitrogen in the form of urea.
Instead, glutamine synthesis is the predominant route for
nitrogen removal in the brain under both normal and
hyperammonemic conditions (Cooper et al., 1979; Felipo
and Butterworth, 2002). However, the glutamine synthase
reaction occurs almost exclusively in astrocytes, and has a
relatively low capacity for dealing with excess ammonia. We
propose that a possible secondary nitrogen removal system in
the brain could conceivably involve NAA synthesis and
excretion (see Fig. 10). Miller and colleagues used radiolabeled
NAA infusion experiments to study NAA metabolism and
found that after catalysis, the aspartate moiety was not
reutilized for NAA synthesis (Miller et al., 1996). They
suggested that these results indicated that one function of NAA
was to transport amino group nitrogen from mitochondria to
cytoplasm. Therefore it is possible that as the brain’s nitrogen
load is increased, Asp-NAT could act to trap some aspartate as
NAA, and neurons could increase their release of NAA to the
extracellular space. It has been reported that NMDA application
can stimulate a calcium-dependent release of NAA from
neurons, but release was not stimulated by hyperosmotic
conditions or potassium-induced depolarization (Tranberg
et al., 2004). In another study, application of NMDA to brain
slices resulted in the release of different metabolites than were
released after potassium induced depolarization or glutamate
application (Thatcher et al., 2002). NAA levels and energy state
were decreased by NMDA application, and lactate levels were
increased. Such findings suggest that NAA is associated with
energy state, and that its release from neurons is a
physiologically regulated response to NMDA receptor activity.
Thus, the lack of a degradative enzyme for NAA in neurons
could serve in part as a secondary nitrogen removal system that
works in conjunction with the astrocyte glutamine excretion
system to eliminate excess nitrogen from the brain. Once
aspartate is acetylated in neurons, NAA only has two known
routes of further catabolism. First, it can be transferred to
oligodendrocytes for degradation to acetate and aspartate, and
subsequent lipid synthesis or energy metabolism. Second, NAA
can be released from neurons to the extracellular space where it
would be taken up by astrocytes via the NaDC3 transporter and
then excreted to the circulation. NAA released to the circulation
could be metabolized in other tissues, in particular kidney,
which expresses ASPA at higher levels than brain (D’Adamo
et al., 1973). It is possible that one function of kidney ASPA
involves scavenging of aspartate and acetate from the low levels
of NAA in the circulation, which would be especially important
when diet was poor (Wolfe, 2005). In this regard it is interesting
to note that the NaDC3 dicarboxylate transporter has recently
been localized to proximal kidney tubule cells (Bai et al., 2006),
the same cell type in the kidney in which ASPA is present.
The greatly increased concentration of NAA that occurs in
the urine of Canavan disease patients clearly indicates that
normally, the majority of NAA produced in the brain is
metabolized to acetate and aspartate, either in oligodendrocytes
in the CNS, or after transport via the circulation, in kidney
proximal tubules cells. It is interesting to note that in liver,
which has a robust urea cycle, aspartate is conjugated to
citrulline to form arginosuccinate as part of the urea cycle, and
that the nitrogen atoms coming from aspartate and citrulline are
eventually incorporated into urea and excreted. Therefore, the
removal of nitrogen from the brain in the form of NAAmay be a
brain-specific mechanism for excretion of aspartate-associated
nitrogen. Within the context of the hypothesis that NAA is
involved in nitrogen removal from the brain, a lack of ASPA
activity in brain and kidney explains the very large accumula-
tion of NAA in urine during Canavan disease, because both
catalytic compartments (oligodendrocytes and proximal tubule
cells) are incapable of degrading NAA. The fact that brain
levels of NAA only rise modestly in Canavan disease, whereas
urine levels increase dramatically, indicates that excess NAA is
efficiently cleared from the brain.
8. Summary and future directions
NAA remains an enigmatic molecule, but researchers are
beginning to decipher the complex web of CNS biochemistry in
which it is actively involved. NAA is one of the most prominent
metabolites in magnetic resonance spectrograms of brain, and
the measured levels are highly sensitive to brain injury or
disease, providing an invaluable tool for diagnosis and
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evaluation in clinical settings. Increases in MRS sensitivity and
reduced voxel size, in conjunction with emerging scanner
technologies and computer techniques will dramatically
improve the diagnostic capabilities of MRS in coming years.
Whereas some proposed functions for NAA, such as an
osmoregulatory role, remain tentative, other functions are now
established, including a role in CNS fatty acid and steroid
synthesis, particularly with respect to postnatal myelination. It
is important to note that NAA provides a means for moving
acetate and aspartate from neurons to oligodendrocytes, but the
transport mechanisms underlying neuronal export and oligo-
dendrocyte uptake of NAA remain to be determined. Many of
the unique biochemical mechanisms of myelin lipid synthesis
in the brain are poorly understood, and much additional
research into the biochemistry of acetate utilization in the CNS
is warranted, both as a building block for lipids, and as an
energy source. The regulatory mechanisms which control the
unique enzymes involved in CNS myelin lipid synthesis have
only been cursorily examined, offering many opportunities for
investigation. Further research into the precise etiology of
Canavan disease is required to determine the best course of
action in dealing with this fatal genetic disorder, including
additional research into ASPA gene therapy and acetate
supplementation. The proposed connections between NAA and
neurotoxicity or disrupted osmoregulation associated with
errors in NAA catabolism remain to be confirmed.
NAA appears to be a direct precursor for the enzymatic
synthesis of the neuronal neuropeptide NAAG, which itself has
important functions including the modulation of neurotransmit-
ter release. How NAAG is synthesized from NAA remains a
mystery, and further work will be required to identify the
enzyme(s) responsible. Only limited research has been directed
toward determining how the biosynthesis of either NAA or
NAAG is regulated at the genetic or enzymatic levels, and
purification of the enzymes involved, and identification of their
respective genes will be crucial in furthering our understanding
of these regulatory mechanisms. There is substantial evidence
that NAA synthesis in neuronal mitochondria is tied to neuronal
energymetabolism, but this topic is far from resolved, especially
with respect to the relatively low turnover rate of NAA in the
brain. The emerging bioenergetic functions of NAA in the
nervous system are tantalizing targets for further research in part
due to the established connection between neuronal health and
NAA levels as revealed bymagnetic resonance spectroscopy and
other methods. The hypothesis that NAA excretion works in
conjunction with glutamine excretion in regulating brain
nitrogen balance is worthy of investigation. Because NAA is
found at high concentrations only in the nervous system, the
exceptionally strong expression of the NAA-specific hydrolyz-
ing enzyme ASPA in tissues such as kidney is suggestive of
possible distinct functions in peripheral tissues that may involve
acetylated substrates other than NAA. Also in this regard, the
localization of ASPA in the nuclei of oligodendrocytes and
kidney proximal tubule cells is also suggestive of additional
functional roles for this enzyme. These are potentially fruitful
areas of research into the many complexities of NAA
biochemistry and neurobiology in the central nervous system.
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